SOLID ORAL PHARMACEUTICAL COMPOSITION COMPRISING AN ACTIVE INGREDIENT STIMULATING THE CENTRAL NERVOU

专利摘要:
methods and compositions for treating attention deficit disorder therapeutic compositions and methods for treating attention deficit disorder (ADHD) or attention deficit hyperactivity disorder (ADHD) include dosage forms that deliver a therapeutic amount of the drug active in a sustained and controlled release formulation. the dosage form can be administered at night and the drug release is prolonged for 3 to 8 hours, followed by an ascending release rate.
公开号:BR112013024401B1
申请号:R112013024401-1
申请日:2012-03-23
公开日:2022-01-11
发明作者:David Lickrish；Feng Zhang
申请人:Ironshore Pharmaceuticals & Development, Inc；
IPC主号:

专利说明:

Cross-References to Related Patent Applications
[001] This Application claims priority benefit to US Interim Application No. 61/591,129, filed January 26, 2012, Interim Application No. 61/561,763, filed November 18, 2011, and Interim Application US 61/466,684 , filed on March 23, 2011, the contents of which are hereby incorporated by reference in their entirety for all purposes. Background of the Invention
[002] Hyperactivity Disorder - Attention Disorder (ADHD) is a developmental disorder characterized by symptoms such as impulsivity, hyperactivity and/or inattention. Hyperactivity is common among children with ADHD, but it tends to disappear during adulthood. However, more than half of children with ADHD continue to show some symptoms of inattention throughout their lives.
[003] Stimulant medications are widely used as a pharmacological treatment for the treatment of ADHD. Short-term stimulants were seen to be safe in appropriately selected patients and appear to be well tolerated over five years of treatment. Active pharmaceutical agents now approved in the US for use in treating ADHD or ADD are primarily influencers of dopamine or norepinephrine neural steps. Approved agents include the salts and isomers of amphetamine and methylphenidate, the prodrug dextroamphetamine, lisdexamfetamine dimesylate, and atomoxotine.
[004] One of the challenges of treating ADHD and other conditions sensitive to CNS stimulation is to provide and maintain effective concentration in patients throughout the day and in particular in the early morning hours when cognitive abilities and concentration are at a premium. needed for school or work and in the late afternoon or evening when students usually do their homework. Early formulations relied on twice-daily administration of an immediate-release formulation, causing problems with compliance. Several long-acting formulations have been developed and are now available, which have been shown in clinical studies to be effective from 8-14 hours (Brams et al., Current Medical Research and Opinion, vol 26 No. 8., pp. 1809-1825). , August 2010). Summary of the Invention
[005] The compositions and methods of the present disclosure provide novel formulations and methods for treating diseases or conditions that are sensitive to central nervous system stimulants. Such conditions include, but are not limited to, attention deficit disorder, attention deficit hyperactivity disorder, narcolepsy, excessive daytime sleepiness, major depressive disorder, bipolar depression, negative symptoms of schizophrenia, chronic fatigue, chemotherapy-associated fatigue or binge eating disorder. The compositions and methods are effective in treating the adult, pediatric and adolescent population in need of such treatment.
[006] The compositions and methods described provide a convenient method of administration, wherein a single dose can be taken normally at night before bed, or at any time of day at rest during a long period of sleep and drug release. it is prolonged for 4 to 12 hours in some instances and then released in a controlled or sustained fashion. In certain embodiments, the compositions are water-soluble capsules that contain coated particles, such as granules or mini-tablets. These particles are coated with an outer sustained-release layer and an inner sustained-release coating over a core containing the drug. The sustained release allows the individual to sleep, and when the outer layer of the composition dissolves and the sustained release layer begins to lose some of its integrity, the drug begins to be released slowly. This results in a low but therapeutic level of drug in the patient's serum when the patient would normally wake up and get ready for the day. Subsequent to this slow release, the rate of drug release increases over a period of about eight to ten hours or more to continue to deliver a therapeutic amount during the typically active part of the day. The compositions and methods described herein thus provide a single dose which is conveniently ingested before bedtime, and which provides a therapeutic effect from the time a subject normally wakes up to the productive part of the day.
[007] While the present compositions are described as effective as a once daily dosage, it is understood that additional doses may be administered as needed in accordance with the physician's instructions. The description here is primarily aimed at treating people with a typical schedule of going to sleep around 9 pm until approximately midnight, for example, and sleeping for 6 to 9 hours. It is understood, however, that the use and effectiveness of the compositions and methods are not limited to such a schedule, but can be adopted for use with different daily schedules, such as night workers, or people with longer sleep patterns, shorter or more variable.
[008] In certain embodiments, the compositions described herein include, but are not limited to, tablets, mini-tablets, or granules contained in a water-soluble capsule. The minitablets or granules may include a drug-containing core, or a drug-coated inert granule core, in which the drug core or drug layer may also contain an optional disintegrant, osmotic agent, or pore-forming agent. In certain embodiments, the disintegrant may be a superdisintegrant. In certain embodiments, the drug layer or core is surrounded by a sustained-release layer that may include a water-permeable, water-insoluble polymer layer that controls the rate of water absorption and drug release. The outer sustained-release layer is coated over the sustained-release layer. The extended release layer may contain a plasticizing agent or the solubility is pH dependent. The extended release layer may thus be a pH dependent layer which is insoluble in aqueous solution at a pH below 5.0 and soluble at a higher pH in the ileum or colon, or it may be a pH independent layer. In certain embodiments, a pH-dependent outer layer dissolves at the higher pH of the ilium or colon. As the sustained-release layer loses integrity, then the sustained-release layer breaks down and releases the drug remaining in the core.
[009] Active ingredients include central nervous system stimulants that are effective for treating ADD and ADHD or other conditions associated with the dopamine or norepinephrine neural pathway. Active ingredients include, but are not limited to, the active isomers of amphetamines and salts of amphetamines, including dextroamphetamine and methylphenidate salts and their active salts, all of which can be used as racemic mixtures or pure isomers, such as d-threo- methylphenidate. The disclosed compositions may also include one or more central nervous system stimulant prodrugs, including, but not limited to, active ingredients conjugated to amino acids, such as l-lysine, d-amphetamine, for example.
[0010] The compositions and methods of the present disclosure can be described, in certain embodiments, therefore, as an oral solid pharmaceutical composition including a core comprising a therapeutic amount of a central nervous system stimulant, at least one pharmaceutically excipient. acceptable and optionally a disintegrant, osmotic agent, or pore-forming agent; a sustained release layer lining the core; and an extended-release layer surrounding the sustained-release layer, wherein the combination of the sustained-release and extended-release layers provides three to eight, ten, or even twelve to thirteen hours of extension, during which time no more than 10% of the central nervous system stimulant is released when the composition is placed in a simulated gastric environment. The term simulated gastric medium is intended to be used herein to convey its normal meaning as understood in the art, and is understood in a broad sense to denote an aqueous medium of low pH, for example 1 to 5, followed, after a period of of up to about 2 hours, with immersion in a higher pH aqueous medium, such as pH 6.8, for example, or a three-stage medium, where the low pH is followed by an intermediate pH value of about of 6, wherein the media is maintained at about 37.0°C. Alternatively, for certain embodiments, a simulated gastric medium is described as the USP I apparatus (Cestos), with agitation, in which the composition is placed in an aqueous solution of 700 ml of 0.1N HCl, pH 1.1, for up to 2 hours, followed by 2 to 6 hours in sodium phosphate buffer, pH 6.0, followed by 6 to 20 hours in sodium phosphate buffer, pH 7.2, adding NaOH to adjust the pH to 7.2.
[0011] Any of the solid oral pharmaceutical compositions described herein may be in the form of coated granules, or may be compressed into tablets or mini-tablets. The granules or mini-tablets can then be divided into single-dose amounts in water-soluble gelatin capsules, or in a liquid or gel suspension for administration.
[0012] One aspect of the compositions and methods of the present invention may also be described as a solid oral pharmaceutical composition including a core comprising a therapeutic amount of a central nervous system stimulant and at least one pharmaceutically acceptable excipient, wherein the core is substantially free of a disintegrating agent, osmotic agent, or pore-forming agent; a sustained release layer lining the core; and an extended-release layer surrounding the sustained-release layer, wherein the combination of the sustained-release and extended-release layers provides a 3 to 12 hour extension during which no more than 10% of the central nervous system stimulant is released when the composition is placed in a simulated gastric medium.
[0013] An oral solid pharmaceutical composition of this disclosure may be described as a formulation wherein the in vitro dissolution rate of the dosage form, as measured by USP I apparatus (Baskets) with agitation, wherein the composition is placed in 700 ml of 0.1N aqueous HCl solution, at pH 1.1, for up to 2 hours, followed by 2 to 6 hours in sodium phosphate buffer at pH 6.0; followed by 6 to 20 hours in sodium phosphate buffer, pH 7.2, adding NaOH to adjust the pH to 7.2 at 37°C ± 0.5°C is between 0 and about 20% of the drug released after 8 hours, between about 2 and about 30% released after 10 hours, between about 10 and about 65% released after 12 hours, and between 45% and 95% released after 15 hours, and where the amount of active ingredient released per hour, increases from the period between 20% release and 65% release. The compositions and methods of the present invention may also be described as an oral solid pharmaceutical composition, wherein the in vitro dissolution rate of the dosage form, as measured by USP I apparatus (Baskets) with agitation, into which the composition is placed in 700 ml of 0.1N aqueous HCl solution at pH 1.1, for up to 2 hours, followed by 2 to 6 hours in sodium phosphate buffer at pH 6.0; followed by 6 to 20 hours in sodium phosphate buffer, pH 7.2, with addition of NaOH to adjust the pH to 7.2, at 37°C ± 0.5°C it is between 0 and about 10% of the drug released after 6 hours, between about 15 and about 28% released after 10 hours, between about 40 and about 60% released after 12 hours, and between about 80% and about 95% released after 15 hours , and wherein the amount of active ingredient released per hour increases from the period between 20% release and 65% release, or as an oral solid pharmaceutical composition as described, when measured by USP I apparatus (Baskets) with agitation, in which the composition is placed in an aqueous solution of 700 ml of 0.1N HCl pH 1.1 for 2 hours, followed by 2 to 6 hours in sodium phosphate buffer pH 6.0; followed by 6 to 20 hours in sodium phosphate buffer, pH 7.2, with addition of NaOH to adjust the pH to 7.2 to 37°C ± 0.5°C, not more than about 10% of the agent is released within 6 hours and no more than about 50% of the agent is released within 12 hours, and wherein, when the composition is administered to a human, a plot of plasma concentration versus time after administration shows a single maximum between 12 and 20 hours after administration.
[0014] The solid oral pharmaceutical compositions of the present invention may further include a series of pellets in the core which, in certain embodiments, are substantially spherical granules. The core may consist essentially of a central nervous system stimulant and one or more excipients, or the core may consist essentially of the stimulant and one or more excipients coated onto a non-pareil inert granule. These cores are then coated with two or more controlled release layers to produce a population of particles for drug delivery. It is an aspect of the compositions and methods of the present disclosure, however, that it is advantageous to provide a smooth spherical core to the extent possible in order to obtain a more consistent coating and reproducible release profile of the active ingredient from the particle populations. .
[0015] The oral solid pharmaceutical compositions of the present application also include a central nervous system stimulant which can be generally defined as a chemical entity that affects the dopamine or norepinephrine neural pathways. Preferred pharmaceutically active ingredients include, but are not limited to, amphetamine, dextroamphetamine, the active isomers of amphetamine and amphetamine salts, including the salts of dextroamphetamine, methylphenidate and their active salts or combinations thereof, all of which may be used as mixtures. racemics or pure isomers, such as d-threo-methylphenidate, or a pharmaceutical salt or prodrug, or the mixed pharmaceutical salts of any of these alone or in combination. The disclosed compositions may also include a prodrug, including, but not limited to, active ingredients conjugated to amino acids, such as 1-lysine-d-amphetamine. Suitable excipients in the core of the pharmaceutical composition may include polyvinylpyrrolidone, hydroxypropyl methylcellulose, lactose, sucrose, microcrystalline cellulose or combinations of any of these.
[0016] It is an aspect of the disclosed compositions that the extended release layer may include a pH-dependent polymer or copolymer that is insoluble in aqueous media at pH less than 5.5. Such a sustained release layer may include, but is not limited to, cellulose acetate phthalate, cellulose acetate trimaleate, hydroxylpropyl methylcellulose phthalate, polyvinyl acetate phthalate, acrylic polymers, polyvinyl acetate acetaldiethylamino, acetate succinate of hydroxypropyl methylcellulose, cellulose acetate trimellitate, shellac, methacrylic acid copolymers, Eudragit L30D, Eudragit L100, Eudragit FS30D, Eudragit S100 or combinations thereof. The extended release layer may also include a plasticizing agent, or, in certain embodiments, the extended release layer may include Type B methacrylic acid copolymer, mono- and di-glycerides, dibutyl sebacate, and polysorbate 80.
[0017] In certain embodiments of the disclosed solid oral pharmaceutical compositions, the sustained release layer includes a water-insoluble, water-permeable polymer and may further include a water-soluble polymer. In certain embodiments, the sustained release layer includes, but is not limited to, a cellulose ether derivative, an acrylic resin, a copolymer of acrylic acid and methacrylic acid esters with quaternary ammonium groups, a copolymer of acrylic and methacrylic acid esters, or a combination of any of these, or may include ethyl cellulose, hydroxypropyl cellulose, dibutyl sebacate and magnesium stearate.
[0018] In some embodiments, the core may include a disintegrating agent and may include corn starch, potato starch, a pregelatinized starch, a modified starch, a sweetener, a clay, bentonite, microcrystalline cellulose, calcium carboxymethyl cellulose , croscarmellose sodium, alginic acid, sodium alginate, potassium polyacryline cellulose, an alginate, sodium starch glycollate, a gum, agar, guar, locust bean, karaya, pectin, tragacanth, crospovidone or low-substituted hydroxypropylcellulose. The compositions may also include a disintegrating agent, osmotic agent, or a pore-forming agent, which may be a salt, an acid, a base, a chelating agent, sodium chloride, lithium chloride, magnesium chloride, magnesium, lithium sulfate, polyol, mannitol, sulfate, xylitol, a carbohydrate, a carbonate, a bicarbonate, electrolyte, potassium chloride, sodium sulfite, calcium bicarbonate, sodium sulfate, calcium sulfate, calcium lactate, d -mannitol, urea, tartaric acid, raffinose, sucrose, alpha-d-lactose monohydrate, glucose, alpha-hydroxy acids, citric acid, ascorbic acid, or a combination of any of these. It is yet another aspect of the present application that the disclosed formulations may include an abuse deterrent agent, which may be a nasal irritant such as a capsaicinoid or sodium lauryl sulfate.
[0019] In certain embodiments, the optional disintegrant, osmotic agent, or pore-forming agent constitutes from 0 to about 75% of the core by weight. The compositions may also include a swellable layer or a sealing layer disposed between the core and the sustained-release layer. The swellable layer may include a superdisintegrant, an osmotic agent, or a combination thereof, and in certain embodiments includes a hydrophilic polymer such as polyethylene oxide and a binder and may further include a drug-containing layer between the swellable layer and the sustained release layer, which may also include a seal between the swellable layer and the drug-containing layer.
[0020] In certain embodiments, the compositions and methods of the present disclosure may be described as a method of treating a condition in a subject with a disorder or condition responsive to administration of a central nervous system stimulant, comprising oral administration of the oral solid pharmaceutical compositions. The method of treatment may include administration of a single dosage form or two daily doses, depending on the particular patient's need. It is an aspect of the compositions and methods of the present disclosure that administration of the dosage form, on a once-a-day basis, provides a sustained release of about 4 to about 12 hours, followed by a plasma concentration profile. increasing, which over a 24 hour period beginning with one administration of the dosage form results in a single peak serum concentration (Cmax), which occurs at least 12 hours, at least 14 hours, or at least 15 hours after administration.
[0021] The compositions and methods of the present disclosure may also be described in certain embodiments, as an oral solid pharmaceutical composition including a therapeutic amount of a central nervous system stimulant wherein the composition, when administered orally to a human , provides a sustained release of 4 to 12 hours, an increasing serum concentration of central nervous system stimulant over a period of 7 to 12 hours, and a maximum serum concentration (Cmax) of 10 to 16 hours after administration. In certain embodiments, the serum concentration has a single maximum.
[0022] The compositions and methods of the present disclosure may also be described in certain embodiments, such as a solid oral pharmaceutical composition comprising a core comprising a therapeutic amount of a central nervous system stimulant and at least one pharmaceutically excipient. acceptable wherein the core is substantially free of a disintegrating agent, osmotic agent, or pore-forming agent; a sustained release layer lining the core; and an extended-release layer surrounding the sustained-release layer, wherein, when the composition is placed in a simulated gastric environment, the combination of the sustained-release and extended-release layers provides: a significant 3-12 hour delay during which no more than 10% of the central nervous system stimulant is released and an upward average release of the central nervous system agent 8 to 16 hours after being placed in the simulated gastric medium.
[0023] Conditions or disorders that can be treated include, but are not limited to, attention deficit disorder, attention deficit hyperactivity disorder, excessive daytime sleepiness, major depressive disorder, bipolar depression, negative symptoms of schizophrenia, chronic fatigue , fatigue associated with chemotherapy or binge eating disorder. Attention deficit disorders are characterized by symptoms of hyperactivity, impulsivity, or inattention that impair social, academic, or professional functioning, and are often present in two or more settings, school (or work) and at home, for example. For the Inattentive Type, at least six of the following symptoms persisted for at least 6 months: lack of attention to detail/careless mistakes; lack of sustained attention; inattentive listener; failure to follow up on tasks; bad organization; avoid tasks that require sustained mental effort; loss of objects; easily distracted and forgetfulness. For the Hyperactive-Impulsive Type, at least six of the following symptoms persisted for at least 6 months: fidgeting/squirming; not stop sitting; inappropriate running/climbing; difficulty with quiet activities; "always in movement"; excessive speech; answers given impulsively; not being able to wait one's turn, and inconvenient attitude. The combined type includes both inattentive and hyperactive-impulsive behaviors.
[0024] It is understood that the term treatment as used herein is not limited to the cure or elimination of any condition or disorder, nor is this term limited to the achievement of certain goals or improvement criteria in a certain individual, but includes the administration of an agent with the aim of achieving positive effects in terms of cognitive or behavioral function, reduction of symptoms or side effects. All of these activities are considered treatment with or without any immediately observable or measurable improvement.
[0025] It is known, for example, that certain side effects may occur in conjunction with the administration of CNS stimulants. These side effects may include, but are not limited to, headache, nausea, dizziness, hot flashes, decreased appetite, insomnia, abdominal discomfort (stomach pain), dry mouth, tachycardia, nervousness, mood swings, irritability, wasting of weight or complaints of not feeling well. It is believed that treatment with the disclosed formulations will result in a lower incidence or severity of side effects relative to treatments in which the active agent is rapidly released in the stomach. As such, treatment could encompass not only reducing symptoms of the condition or disorder, but also reducing side effects.
[0026] The compositions and active agents of the present invention are administered in an "effective amount", "effective dose", or "therapeutically effective amount". By an "effective" amount or a "therapeutically effective amount" or dose of a drug or pharmacologically active agent is meant a non-toxic but sufficient amount of the drug or agent to provide the desired effect. In the current disclosure, an "effective amount" is that amount of that composition or active agent that is effective to ameliorate, alleviate, or prevent one or more symptoms of the condition being treated. The amount that is "effective" will vary from person to person, depending on the age and general condition of the individual, or the particular active agent. An effective or therapeutic dose or amount is determined by a physician and is often based on empirical data obtained by administering increasing doses until the best balance of benefit versus side effects is obtained.
[0027] An effective dose in the compositions of the present invention, in particular for the treatment of ADHD includes doses shown to be effective in the treatment of said oral dosing conditions, including but not limited to 5, 9, 10, 15, 18, 20, 25, 27, 30, 35, 36, 45 or 54 mg once or twice a day. It is also understood that other dosage ranges may be effective for conditions or symptoms other than ADHD and, as such, the therapeutically effective drug concentration in the disclosed compositions may be from 0.1 to 1000 mg inclusive of any particular concentration within that range. .
[0028] As used herein, the term "pharmaceutically acceptable salt" refers to non-toxic, pharmaceutically acceptable salts as described in (Ref. International J. Pharm, 1986, 33, 201-217, J. Pharm. Sci. 1997 (January), 86, 1, 1). Other salts well known to those skilled in the art may, however, be useful in preparing the compositions of the present disclosure, including, but not limited to, hydrochloric, hydrobromic, hydroiodic, perchloric, sulfuric, nitric, phosphoric, acetic, propionic, glycolic, lactic, succinic, maleic, fumaric, malic, tartaric, citric, benzoic, mandelic, methanesulfonic, hydroxyethanesulfonic, benzenesulfonic, oxalic, pamoic, 2-naphthalenesulfonic, p-toluenesulfonic, salicylic, cyclohexanesulfamic, saccharine or trifluoroacetic acid. Representative organic or inorganic bases include, but are not limited to, basic or cationic salts such as benzathine, chloroprocaine, choline, diethanolamine, ethylenediamine, meglumine, procaine, aluminum, calcium, lithium, magnesium, potassium, sodium and zinc.
[0029] The compositions and methods of the present invention may also be described in certain embodiments, as an oral solid pharmaceutical composition comprising a therapeutic amount of a central nervous system stimulant wherein the composition, when orally administered to a subject human, provides an extended release of 3 to 8 hours, an ascending rate of central nervous system stimulant release over a period of 7 to 12 hours, and a serum concentration Cmax of 10 to 16 hours after administration, and where a plot of serum concentration versus time after release shows a single maximum. The solid oral pharmaceutical composition can be further defined as one in which not more than 10% of the central nervous system stimulant is released within 6 hours of administration.
[0030] In certain embodiments, the compositions and methods of the present invention may be defined as a solid oral pharmaceutical composition comprising: a core comprising a therapeutic amount of a central nervous system stimulant and at least one pharmaceutically acceptable excipient, a layer a sustained-release layer coating the core, and a sustained-release layer surrounding the sustained-release layer, wherein the core is substantially free of a disintegrating agent, osmotic agent, or a pore-forming agent; wherein, when the composition is administered to a human, the combination of sustained and extended release layers provides: an average of 3 to 8 hours of delay, during which no more than 10% of the central nervous system stimulant is released; an ascending mean of the serum concentration of central nervous system agent from the beginning of absorbance to a period of 12 to 16 hours after administration and in which the serum concentration has a single maximum. Brief Description of Drawings
[0031] The following drawings form part of the present specification and are included to further demonstrate certain aspects of the present invention. The disclosure may be better understood by reference to one or more of these drawings in combination with the detailed description of the specific embodiments presented herein.
[0032] Figure 1A is a schematic representation of a granule-shaped pharmaceutical composition with a drug-containing core surrounded by a sustained-release layer and a sustained-release layer. FIG. 1B is a composition as in Figure 1A with an added swellable layer disposed between the sustained-release layer and the extended-release layer.
[0033] Figure 2A is a schematic representation of a mini-tablet pharmaceutical composition with a drug-containing core surrounded by a sustained-release layer and an extended-release layer. FIG. 2B is a composition as in 2A with an added swellable layer disposed between the sustained-release layer and the extended-release layer.
[0034] Fig. 3 is a schematic representation of a pharmaceutical composition in granule form that includes a core surrounded by four layers, an inert inner core, a swellable polymer, a drug layer, a sustained release layer and a layer enteric.
[0035] Fig. 4 is a graph of the dissolution profiles of DOE 1 to 8.
[0036] Fig. 5 is a graph of the dissolution profiles of DOE 9, 10, 11, 3, 4.
[0037] Fig. 6 is a graph of the dissolution stability profile of DOE 4.
[0038] Fig. 7 is a graph of the dissolution stability profile of DOE 3.
[0039] Fig. 8 is a graph of enteric coating on the dissolution profile of DOE 3 (Stage-3).
[0040] Fig. 9 is a graph of the dissolution of DOE 3 coatings.
[0041] Fig. 10 is a graph of the dissolution profile of batch 2009-138-45 (30% weight gain).
[0042] Fig. 11 is a graph of the two-week dissolution stability profile.
[0043] Fig. 12 is a graph of the dissolution profile of DOE 3 (Lot 2009-138-45) cured at 50°C.
[0044] Fig. 13 is a graph of the dissolution profile of DOE 3 (Lot 2009-138-45) cured at 55°C.
[0045] Fig. 14 is a graph of the dissolution profile of DOE 3 (Lot 2009-138-45) cured at 55°C in the stable mode.
[0046] Fig. 15 is a graph of the dissolution profile of DOE 3 (Lot 2009-138-45), 8 month stability.
[0047] Fig. 16 is a graph of the dissolution profiles of the formulations described in Examples 14-18.
[0048] Fig. 17 is a graph of the serum concentration of healthy volunteers after ingestion of the formulations of Examples 14-18.
[0049] Fig. 18 is a comparison of the data of FIG. 17 with the commercially available formulations. Detailed Description of the Invention
[0050] The present invention provides therapeutic compositions and methods for treating attention deficit disorder (ADD), attention deficit hyperactivity disorder (ADHD) or other stimulant sensitive conditions or disorders of the central nervous system, providing dosage forms that deliver a therapeutic amount of the active drug in a sustained-release and controlled-release pattern so as to maintain a therapeutic amount of the drug during the active part of the day. For pediatric patients, including teenagers and adults alike, a therapeutic amount is desirable upon rising and throughout the morning, as well as during the afternoon hours when work or housework needs to be done.
[0051] The described formulations can deliver a therapeutic amount of the drug over long periods of the day with a single administration. The dosage forms provide for an extended release such that the dosage form can conveniently be administered prior to the patient's sleep period. A small percentage of the drug may be released during the first 6 to 8 hours after administration such that the patient has already received a minimal therapeutic dose by the normal awakening time. The patient thus does not need to be woken up to take a pill and then forced to eat breakfast and be prepared for his day before experiencing a therapeutic effect.
[0052] The formulations described herein also provide for increased drug release over the next 8 to 16 hours or longer after the delay period, or up to 16 hours after administration of the dosage forms. Dosage forms can thus provide an extended release followed by a sigmoid release curve, as shown in the accompanying drawings in the Figures. 3 and 5. Central Nervous System Stimulants
[0053] Stimulant medications (eg, methylphenidate and amphetamines and prodrugs) are often prescribed to treat individuals diagnosed with attention deficit hyperactivity disorder (ADHD). According to the National Institute of Health, all stimulants work by increasing levels of dopamine in the brain. Dopamine is a brain chemical (or neurotransmitter) associated with pleasure, movement, and attention. The therapeutic effect of stimulants is achieved by a slow and steady increase in dopamine, similar to the natural production by the brain. Dosages prescribed by doctors start off low and gradually increase until a therapeutic effect is achieved.
[0054] Treatment of ADHD with stimulants, often in conjunction with psychotherapy, helps improve the symptoms of ADHD, as well as the patient's self-esteem, cognition, and social and family interaction. The most commonly prescribed medications include amphetamines and methylphenidate. These medications have a calming and paradoxically "focusing" effect on individuals with ADHD. The researchers speculate that because methylphenidate amplify dopamine release, it may improve attention and focus in individuals who have weak dopamine signals.
[0055] Amphetamines that are useful in the formulations and methods described include amphetamines and their isomers, such as dextroamphetamine, d,l amphetamines, and their pharmaceutically acceptable salts, such as sulfate, saccharate, and aspartate salts, for example. Amphetamines are non-catecholamines, sympathomimetic amines with CNS stimulant activity. Peripheral actions include elevations in systolic and diastolic blood pressure and weak bronchodilator and respiratory system stimulant action.
[0056] Dextroamphetamine is the dextro isomer of the compound d,l - amphetamine sulfate, a sympathomimetic amine of the amphetamine group. Chemically, dextroamphetamine is d-alpha-methylphenethylamine. Dextroamphetamine can be used in the practice of the present disclosure, or the various pharmaceutically acceptable salts of dextroamphetamine can be used. Methylphenidate
[0057] Methylphenidate is another central nervous system (CNS) stimulant that has been used since the 1960s for the treatment of ADD, ADHD, fatigue, and narcolepsy. Methylphenidate can be prescribed in a racemic mixture of dextro and levo conformations or as the pure dextro isomer. Methylphenidate has two chiral centers in the molecule and therefore can also be further refined to enrich the d-threo isomer. The use of pharmaceutically acceptable salts of methylphenidate, such as methylphenidate hydrochloride, are also contemplated by the present disclosure.
[0058] It is understood that the active pharmaceutical ingredients of the present disclosure may be present as prodrugs that are activated in the user's body. A prodrug form has an amino acid conjugated to the active ingredient. When the amino acid is enzymatically cleaved, the active drug is released. Prodrugs comprising a lysyl, isoleucyl or aspartyl conjugate are considered useful in the practice of the present disclosure. Formulations
[0059] The formulations of the disclosure are designed to provide novel and serum release profiles that include a first delay phase followed by a sigmoid release phase. By providing this profile, the dosage forms provide a timed, prolonged therapeutic effect when taken once daily. Based on the release characteristics in which the dosage form passes through the stomach before being released, the formulations disclosed herein should provide at least the following additional advantages, low variability of gastric emptying, low dependence on nutritional status (fed or in fasting), low risk of sudden dose emptying and low intra- and inter-individual variability.
[0060] A first example of a dosage form is a single population of granules that can be administered in a capsule or in a liquid or gel suspension containing the granules. An example of a granule structure 10 is shown schematically in FIG. 1A-B. In fig. 1A, the inner circle represents a drug-containing core, which includes the active ingredient, or prodrug, suitable excipients, and, optionally, an osmotic agent or superdisintegrant. A core can include, for example, an active agent, a disintegrating agent, osmotic agent or pore-forming agent, and a binder. An exemplary core includes about 20 to 25% active agent, about 45 to 60% microcrystalline cellulose, about 10 to 30% potassium chloride, and about 3 to 5% binder such as polyvinylpyrrolidone or hydroxypropyl cellulose, for example. The drug-containing core can be made by a number of processes known in the art, including wet granulation, extrusion and sphering. In this embodiment, two layers cover the core. The first layer is a sustained-release layer and the outer layer is a sustained-release layer, which is optionally pH dependent. In certain embodiments, the core as shown in FIG. 1A may be an inert non-pareil granule. The inner core is a granule of sugar and starch, or it may be composed of microcrystalline cellulose. Any spherical granule which is suitable for forming the core granule and being pharmaceutically acceptable can be used. In such embodiments, the drug and core excipients are layered over the core granule providing a three-layer formulation.
[0061] The outermost layer 14 is a sustained release or enteric coating. In certain embodiments this layer comprises a water-soluble polymer, a water-insoluble polymer, a plasticizer and a lubricant. The drug release delay time is controlled by the ratio of water-soluble to water-insoluble polymers, the plasticizer concentration, the amount of lubricant, and the coating weight gain, which can be up to 35 to 45%. Alternatively, this layer is a pH dependent polymer that dissolves at a pH above 5.0.
[0062] A sustained release layer 16 is designed to provide a slower initial release rate that increases over a period of up to 8 to 10 hours after the layer is exposed to an aqueous medium. The increasing drug profile can be achieved by a membrane that becomes more permeable over time. An example of a sustained release layer includes a water-soluble polymer, a water-insoluble polymer, a plasticizer, and a lubricant. The drug release rate can be controlled or sustained by varying the proportion of water-insoluble and water-soluble polymers and varying the coating thickness until a weight gain of 15 to 45%.
[0063] An alternative embodiment is shown in FIG. 1B. In this figure, a swellable layer 18, which includes a superdisintegrating agent or osmotic agent, is disposed between the core and the sustained release layer.
[0064] In certain embodiments, the compositions and methods of the present invention include a four-layer formulation 30, as shown in FIG. 3. This formulation may include an inner core 15 of a non-pareil granule and four concentric layers from the inside to the outside, described as a swellable polymer layer 18, the drug layer 12, a sustained release layer. 16 and a pH dependent sustained release layer 14, which may be a pH dependent layer.
[0065] In certain embodiments, the composition of 4 layers can be done gradually. In the first step, a hydrophilic polymer suspended in ethanol with a binder is coated onto non-pareil granules at a weight gain of 30 to 50%. In certain embodiments Polyox Coagulant SFP (PEO), marketed by The Dow Chemical Company is the hydrophilic polymer and hydroxypropyl cellulose (HPC LF) is added as the binding agent. The PolyOx layer is then sealed with hydroxypropyl cellulose such as Klucel® EF at a 10% weight gain. The API is then suspended in ethanol with a binder and coated over the layered granule and the sustained release and extended release coatings are applied as described herein.
[0066] Figs. 2A-B depict embodiments where the core is a mini-tablet 20 rather than a granule. The core and layers in Figs. 2A and B are functionally the same as the numbered layers on the granules in Figure 1A-B, except there is no optional inert core.
[0067] Various water-soluble polymers can be used in the disclosed formulations. These polymers include, but are not limited to, polyethylene oxide (PEO), propylene oxide-ethylene oxide copolymers, polyethylene-polypropylene glycol (e.g. poloxamer), carbomer, polycarbophil, chitosan, polyvinylpyrrolidone ( PVP), polyvinyl alcohol (PVA), hydroxyalkyl celluloses such as hydroxypropyl cellulose (HPC), hydroxyethyl cellulose, hydroxymethyl cellulose and hydroxypropyl methyl cellulose, sodium carboxymethyl cellulose, methyl cellulose, hydroxyethyl methyl cellulose, hydroxypropyl methyl cellulose, polyacrylates such as carbomer, polyacrylamides, polymethacrylate lamides, polyphosphazines, polyoxazolidines, polyhydroxyalkyl carboxylic acids, alginic acid and derivatives thereof such as carrageenan alginates, ammonium alginate and sodium alginate, starch and starch derivatives, polysaccharides, carboxypolymethylene, polyethylene glycol, natural gums such as guar gum, acacia gum, tragacanth gum, karaya gum and xanthan gum, povidone, gelatin or the like.
[0068] In certain embodiments, at least the extended release layer includes one or more polymers, such as an acrylic polymer, acrylic copolymer, methacrylic polymer, or methacrylic copolymer, including but not limited to Eudragit® L 100, Eudragit® L100-55, Eudragit® L 30 D-55, Eudragit® S100, Eudragit® 4135F, Eudragit® RS, acrylic acid copolymers and methacrylic acid copolymers, methyl methacrylate, methyl methacrylate copolymers, ethacrylates xyethyl, cyanoethyl methacrylate, aminoalkyl methacrylate copolymer, polyacrylic acid, polymethacrylic acid, methacrylic acid-alkylamine copolymer, polymethyl methacrylate, polymethacrylic acid anhydride, polymethacrylate, polyacrylamide, polymethacrylic acid anhydride and glycidyl methacrylate copolymers , an alkyl cellulose such as ethyl cellulose, methyl cellulose, calcium carboxymethyl cellulose, some substituted cellulose polymers, such as hydroxypropyl methyl cellulose phthalate, and hydroxypropyl methylcellulose acetate succinate, cellulose acetate butyrate, cellulose acetate phthalate, cellulose acetate trimaleate, polyvinyl acetate phthalate, polyester, waxes, shellac, zein, or the like.
[0069] Eudragits are well known polymers and copolymers useful for controlled release applications. EUDRAGIT® grades for enteric coating types are based on anionic polymers of methacrylic acid and methacrylates. They contain -COOH as a functional group. They dissolve in the ranges of pH 5.5 to pH 7. EUDRAGIT® FS 30 D is the aqueous dispersion of an anionic copolymer based on methyl acrylate, methyl methacrylate and methacrylic acid. It is insoluble in acidic media, but dissolves by salt formation above pH 7.0. Eudragit L100-55 and L30-55 dissolve at a pH above 5.5. Eudragit L100 and S 100 dissolve at pH above 6.0.
[0070] Sustained-release formulations of EUDRAGIT® are employed for many oral dosage forms to allow time-controlled release of active ingredients. Drug distribution can be controlled throughout the gastrointestinal tract for increased therapeutic effect and patient compliance. Different polymer combinations of EUDRAGIT® grades RL (easily permeable) and RS (moderately permeable) allow for tailored release profiles and allow for a wide range of alternatives to achieve desired drug delivery performance. EUDRAGIT® NE polymer is a neutral ester dispersion that does not require any plasticizing agent and is particularly suitable for granulation processes in the manufacture of matrix tablets and sustained release coatings.
[0071] Examples of osmotic or osmaging agents include organic and inorganic compounds such as salts, acids, bases, chelating agents, sodium chloride, lithium chloride, magnesium chloride, magnesium sulfate, lithium sulfate, potassium chloride, sodium sulfite, calcium bicarbonate, sodium sulfate, calcium sulfate, calcium lactate, d-mannitol, urea, tartaric acid, raffinose, sucrose, alpha-d-lactose monohydrate, glucose, combinations thereof and other similar materials or equivalents that are widely known in the art.
[0072] As used herein, the term "disintegrant" is understood to mean a compound used in solid dosage forms to promote the breakdown of a solid mass (layer) into smaller particles that are more easily dispersed or dissolved. Examples of disintegrants include, by way of example and without limitation, starches such as corn starch, potato starch, pregelatinized starches and the modified starches thereof, sweeteners, clays, bentonite, microcrystalline cellulose (e.g. Avicel™ ), calcium carboxymethyl cellulose, croscarmellose sodium, alginic acid, sodium alginate, potassium polyacryline cellulose (e.g. Amberlite™), alginates, sodium starch glycollate, gums, agar, guar, locust bean, karaya, pectin, tragacanth , crospovidone and other materials known to those skilled in the art. A superdisintegrant is a fast acting disintegrant. Examples of super-disintegrants include crospovidone and weakly substituted HPC.
[0073] In preferred embodiments, a plasticizer is also included in the oral dosage form. Plasticizers suitable for use in the present invention include, but are not limited to, low molecular weight polymers, oligomers, copolymers, oils, small organic molecules, low molecular weight polyols having aliphatic hydroxyl groups, ester-type plasticizers, glycol, poly(propylene glycol), multiblock polymers, single block polymers, low molecular weight polyethylene glycol, citrate-ester type plasticizers, triacetin, propylene glycol and glycerin. These plasticizers may also include ethylene glycol, 1,2-butylene glycol, 2,3-butylene glycol, styrene glycol, diethylene glycol, triethylene glycol, tetraethylene glycol and other compounds of poly(ethylene glycol), monoisopropyl ether of monopropylene glycol, ether propylene glycol monoethyl ether, ethylene glycol monoethyl ether, diethylene glycol monoethyl ether, sorbitol lactate, ethyl lactate, butyl lactate, ethyl glycolate, dibutyl sebacate, acetyl tributyl citrate, triethyl citrate, acetyl triethyl citrate, tributyl citrate and allyl glycolate.
[0074] It is an aspect of the compositions and methods of the present disclosure that the formulations or dosage forms may further incorporate one or more ingredients that discourage or prevent abuse of the active ingredients by grinding and inhaling a powdered form of the formulations. As such, a nasal irritant can be included either as a separate layer, or incorporated into an outer layer, a sustained release layer or the core of dosage forms. Exemplary irritants include, but are not limited to, sodium lauryl sulfate, which is also called sodium dodecyl sulfate, or capsaicinoids including capsaicin and synthetic capsaicins. In certain embodiments, the dosage forms include from 1 to 10% sodium lauryl sulfate.
[0075] The compositions of the present disclosure may also include one or more functional excipients, such as lubricants, thermal lubricants, antioxidants, buffering agents, alkalizing agents, binders, diluents, sweeteners, chelating agents, coloring agents, flavoring agents, surfactants, solubilizers, wetting agents. , stabilizing agents, hydrophilic polymers, hydrophobic polymers, waxes, lipophilic materials, absorption enhancers, preservatives, absorbents, crosslinking agents, bioadhesive polymers, retarders, pore formers, and fragrance.
[0076] Lubricants or thermal lubricants useful in the present invention include, but are not limited to, fatty esters, glyceryl monooleate, glyceryl monostearate, carnauba wax, beeswax, vitamin E succinate, and a combination thereof.
[0077] As used herein, the term "antioxidant" is intended to mean an agent that inhibits oxidation and thus is used in preventing deterioration of preparations by oxidation due to the presence of oxygen free radicals or free metals in the composition. These compounds include, by way of example and without limitation, ascorbic acid, ascorbyl palmitate, butylated hydroxyanisole (BHA), butylated hydroxytoluene (BHT), hypophosphorous acid, monothioglycerol, sodium ascorbate, sodium formaldehyde sulfoxylate and sodium metabisulfite and others known to those skilled in the art. Other suitable antioxidants include, for example, vitamin C, sodium bisulfite, vitamin E and its derivatives, propyl gallate or a sulfite derivative.
Binders suitable for use in the present invention include beeswax, carnauba wax, cetyl palmitate, glycerol behenate, glyceryl monostearate, glyceryl palmitostearate, glyceryl stearate, hydrogenated castor oil, microcrystalline wax, wax of paraffin, stearic acid, stearic alcohol, stearate 6000 WL1644, gelucire 50/13, poloxamer 188, and polyethylene glycol (PEG) 2000, 3000, 6000, 8000, 10000 or 20000.
[0079] A buffering agent is used to resist changes in pH following dilution or addition of acid or alkali. Such compounds include, by way of example and without limitation, potassium metaphosphate, potassium phosphate, monobasic sodium acetate and anhydrous and dihydrate sodium citrate, salts of organic or inorganic acids, salts of organic or inorganic bases, and others known of experts in the art,
[0080] As used herein, the term "alkalinizing agent" is intended to mean a compound used to provide an alkaline medium for product stability. These compounds include, by way of example and without limitation, a solution of ammonia, ammonium carbonate, diethanolamine, monoethanolamine, potassium hydroxide, sodium borate, sodium carbonate, sodium bicarbonate, sodium hydroxide, triethanolamine and trolamine and others. known to those skilled in the art.
[0081] Exemplary binders include: polyethylene oxide, polypropylene oxide; polyvinylpyrrolidone: polyvinylpyrrolidone-co-vinyl acetate, copolymers of acrylate and methacrylate, polyethylene, polycaprolactone, polyethylene-co-polypropylene: alkyl celluloses and cellulosic derivatives such as weakly substituted HPC (L-HPC), methylcellulose, hydroxyalkylcelluloses such as hydroxymethylcellulose, hydroxyethylcellulose, hydroxypropylcellulose and hydroxybutylcellulose; hydroxyalkyl alkyl celluloses, such as hydroxyethyl methyl cellulose and hydroxypropyl methyl cellulose; starches, pectins, PLA and PLGA, polyesters (shellac), waxes such as carnauba wax, beeswax, polysaccharides such as cellulose, tragacanth, gum arabic, guar gum and xanthan gum.
[0082] Examples of chelating agents include EDTA and its salts, alpha-hydroxy acids such as citric acid, polycarboxylic acids, polyamines, derivatives thereof, and others known to those skilled in the art.
[0083] As used herein, the term "colorant" is intended to mean a compound used to impart color to solid pharmaceutical preparations (e.g., tablets). Such compounds include, by way of example and without limitation, FD & C Red No. 3, FD & C Red No. 20, FD & C Yellow No. 6, FD & C Blue No. 2, D&C Green No. 5, D&C Orange No. 5, D&C Red No. 8, Caramel and Iron Oxide, Red, Other FD Colors & C. and natural coloring agents such as grape skin extract, red beet powder, beta-carotene, annatto, carmine, turmeric, paprika, and other materials known to those skilled in the art. The amount of coloring agent used will vary, as desired.
[0084] As used herein, the term "flavoring" is intended to mean a compound used to impart a frequent pleasant taste and odor to a pharmaceutical preparation. Examples of flavoring or flavoring agents include synthetic flavoring oils and flavoring aromatics and/or natural oils, extracts from plants, leaves, flowers, fruits and so on, and combinations thereof. These may also include cinnamon oil, wintergreen oil, peppermint oil, clove oil, bay oil, fennel oil, eucalyptus, thyme oil, cedar leaf oil, nutmeg oil, sage oil, bitter almond oil and cassia oil. Other flavors include vanilla, citrus oil including lemon, orange, grape, lime and grapefruit, and fruit essences including apple, pear, peach, strawberry, raspberry, cherry, plum, pineapple, apricot and so on. Flavors that have been found to be particularly useful include orange, grape, cherry and the flavors of commercially available chewing gum and mixtures thereof. The amount of flavoring can depend on a number of factors, including the desired organoleptic effect. Flavors will be present in any amount, as desired by those skilled in the art. Particular flavors are the grape and cherry flavors and citrus flavors such as orange.
[0085] Suitable surfactants include Polysorbate 80, sorbitan monooleate, polyoxymer, sodium lauryl sulfate or others known in the art. Soaps and synthetic detergents can be used as surface-active agents. Suitable soaps include the alkali metal fatty acid, ammonium and triethanolamine salts. Suitable detergents include cationic detergents, for example, dimethyl dialkyl ammonium halides, alkyl pyridinium halides and alkylamine acetates; anionic detergents, e.g. alkyl, aryl and olefin, alkyl, olefin, ether and sulfate monoglyceride and sulfosuccinate sulfonates, non-ionic detergents, e.g. fatty oxides of amines, fatty acid alkanolamides, and poly( oxyethylene)-block-poly(oxypropylene), and amphoteric detergents, for example, alkyl beta-aminopropionates and 2-alkylimidazoline quaternary ammonium salts, and mixtures thereof.
[0086] A wetting agent is an agent that lowers the surface tension of a liquid. Wetting agents may include alcohols, glycerin, proteins, water-miscible solvent peptides such as glycols, hydrophilic polymers, Polysorbate 80, sorbitan monooleate, sodium lauryl sulfate, alkali metal fatty acid, ammonium and salts of triethanolamine, dimethyl dialkyl ammonium halides, alkyl pyridinium halides, and alkylamine acetates; anionic detergents, for example alkyl, aryl and olefin, alkyl sulfonates, ether sulphates and monoglycerides; and sulfosuccinates, non-ionic detergents, eg fatty oxides of amines, fatty acid alkanolamides and poly(oxyethylene)-block-poly(oxypropylene) copolymers, and amphoteric detergents, eg β-aminopropionates of alkyl and quaternary ammonium salts of 2-alkylimidazoline and mixtures thereof.
[0087] Solubilizers include cyclodextrins, povidone, combinations thereof, and others known to those skilled in the art.
[0088] Exemplary waxes include carnauba wax, beeswax, microcrystalline wax and others known to one of skill in the art.
[0089] Exemplary absorption promoters include dimethyl sulfoxide, vitamin E PGS, sodium cholate and others known to one of skill in the art.
[0090] Preservatives include compounds used to prevent the growth of microorganisms. Suitable preservatives include, by way of example and without limitation, benzalkonium chloride, benzethonium chloride, benzyl alcohol, cetylpyridinium chloride, chlorobutanol, phenol, phenylethyl alcohol, phenylmercuric nitrate and thimerosal and others known to those skilled in the art.
[0091] Examples of absorbents include sodium starch glycollate (Explotab(TM), Primojel(TM)), and croscarmellose sodium (Ac-Di-Sol(TM)), cross-linked PVP (Polyplasdone(TM) XL 10), magnesium aluminum silicate (Veegum), clays, PVP, alginates, and alginic acid, calcium carboxymethyl cellulose, microcrystalline cellulose (eg Avicel(TM)), potassium polacrylin (eg Amberlite( TM)), sodium alginate, corn starch, potato starch, pregelatinized starch, modified starch, cellulosic agents, montmorillonite clays (e.g. bentonite), gums, agar, locust bean gum, karaya gum, pectin, tragacanth , and other disintegrating agents known to those skilled in the art.
[0092] A cross-linking agent is defined as any compound that will form cross-links between polymer fractions. A cross-linking agent may include, by way of example and without limitation, an organic acid, an alpha-hydroxy acid, a beta-hydroxy acid. Suitable cross-linking agents include tartaric acid, citric acid, fumaric acid, succinic acid and others known to those skilled in the art.
[0093] Bioadhesive polymers include polyethylene oxide, KLUCEL (hydroxypropyl cellulose), CARBOPOL, polycarbophil, GANTREZ, Poloxamer, and combinations thereof, and others known to those skilled in the art.
[0094] Retardants are agents that are insoluble or poorly soluble polymers with a glass transition temperature (Tg) greater than 45°C, or above 50°C before being plasticized by other agents in the formulation, including other polymers and other excipients. needed for processing. Excipients include waxes, acrylics, cellulosics, lipids, proteins, glycols, and the like.
[0095] Examples of pore formers include water-soluble polymers such as polyethylene glycol, propylene glycol, polaxamer and povidone; binders such as lactose, calcium sulfate, calcium phosphate and the like; salts such as sodium chloride, magnesium chloride and the like; combinations thereof and other similar or equivalent materials that are widely known in the art.
[0096] As used herein, the term "sweetening agent" is intended to mean a compound used to impart a sweet taste to the preparation. Such compounds include, by way of example and without limitation, aspartame, dextrose, glycerin, mannitol, sodium saccharin, sorbitol, sucrose, fructose, and other such materials known to those skilled in the art.
[0097] It should be understood that compounds used in the pharmaceutical formulation art generally serve a variety of functions or purposes. Thus, if a compound designated herein is mentioned only once or is used to define more than one term herein, its purpose or function should not be construed as being limited solely to that indicated purpose or function(s).
[0098] It is an aspect of the compositions and methods of the present disclosure that the disclosed pharmaceutical formulations provide novel release profiles in vivo, and when administered orally to a human. The formulations provide an extension time of 4 to 12 hours, in certain embodiments, followed by 85% drug release over the next nine hours at an escalating dose.
[0099] The dissolution profile is performed under conditions designed to mimic the gastric environment, or the environment that is encountered by an oral composition that is ingested by a human. Although the residence time in the stomach varies, a typical test places the composition in the low pH 0.1N HCl solution for two hours to simulate the residence time in stomach acid. The composition is then placed in an aqueous solution at a higher pH, about pH 6 for 2 to 6 hours followed by a pH typically of 6.8 in order to simulate the middle of the ilium and colon. As used herein, simulated gastric conditions encompass both the first acidic phase and subsequent higher pH phases of a normal human gastrointestinal tract.
[00100] After the prolongation period, the serum concentration increases with about 9 to 10 hours to reach a maximum serum concentration (Cmax). Based on this release profile, a dose taken at 9 pm with a 6-hour extension begins to release drug at approximately 3 hours, and peak serum concentration is reached approximately 16 hours later. At that point, the drug is cleared from the system at essentially the same rate at which it is absorbed.
[00101] It is yet another aspect of the compositions and methods of the present disclosure that the drug may begin to be released slowly during the prolongation period. This release is determined by the composition of the extended release layer as described herein. Some examples of a small release during the time interval are those where no more than about 10% of the drug is released during the 3 and 12 hour extension. It is also understood that a higher percentage of 12%, 15%, 18% or even 20% may be released when the extended release layer becomes more permeable.
[00102] Disclosed herein, therefore, are pharmaceutical preparations for once-daily administration of a central nervous system stimulant for the treatment of conditions responsive to such drugs, such as ADD, ADHD, bipolar depression, narcolepsy, sleep disorders and fatigue. The dosage is formulated to be taken before bed, starting the release after an extension of several hours so that the patient absorbs a sufficient amount of drug to have a therapeutic effect while waking up and preparing to leave for work or school. . It is yet another aspect of the formulations, the fact that the drug is released in an increasing dose throughout the day to overcome any acute tolerance effects and maintain a therapeutic level of the drug.
[00103] One embodiment of the compositions and methods of the present disclosure is a dosage form that includes a capsule enclosing a single population of granules or mini-tablets, which include a core and two or more coatings around the core. The inner core is a mini-tablet or granule containing an active pharmaceutical ingredient (API) and one or more excipients. The core is wrapped in a sustained-release layer and an outer sustained-release layer.
[00104] In certain embodiments the sustained release layer includes a combination of water-soluble polymers and water-insoluble polymers. The sustained release coating may contain a combination of polyethylene oxide and ethyl cellulose, for example, or hydroxypropyl methyl cellulose and ethyl cellulose. One ethylcellulose product that can be used in the dosage forms described is Ethocel™, sold under a trademark of The Dow Chemical Company. The dissolution rate of the sustained-release layer can be controlled by adjusting the ratio of water-soluble polymer to water-insoluble polymer in the coating or layer. The weight ratio of water-insoluble polymers to water-soluble polymers can be adjusted, for example, from 90:10 to 10:90, from 80:20 to 20:80, from 75:25 to 25:75, from 70 :30 to 30:70, from 67.5:33.5 to 33.5:67.5 from 60:40 to 40:60, from 56:44 to 44:56. or to 50:50.
[00105] The sustained release coating may also contain plasticizers such as triethyl citrate (TEC), at levels between 3% to 50% of the combined weight of the polymers. Other coating additives may include titanium dioxide, talc, colloidal silicon dioxide, or citric acid.
[00106] Some examples of sustained release layers are presented in the following table. The various formulations include those in which the proportions of water-insoluble polymers to water-soluble polymers are varied and one in which the proportions are reversed. Citric acid was added to a formula in order to keep the pH in the film microenvironment low to inhibit the dissolution of HPMCAS-LF, which dissolves at pH >5.5 thus creating an extension at the beginning of the dissolution curve. In certain embodiments, the active ingredient, or API, may be included in the sustained release layer. In initial tests, a model drug, metronidazole, was micronized and added to the formulation as a suspension. Any of the suitable API's disclosed, however, can be added to the sustained release layer. Table 1 - Exemplary Sustained Release Layers


[00107] An exemplary core was synthesized as shown in Table 2. In this example, an osmotic agent is added to the core. Table 2

[00108] The sustained release layer with the formula shown in the right hand column (F) of Table 1 was synthesized in a granule containing API. The formula was stated 2009-043-10A when the sustained release layer provided a 25% weight gain and 2009-043-10 when the sustained release layer provided a 35% weight gain. Additional layers were synthesized as shown in columns A and B of Table 1. In column B, the formula in column A was modified such that the colloidal silicon dioxide was removed and the plasticizer was increased by 50% w/w of the level of polymer. All other proportions, as shown in column A, were maintained.
[00109] The formula in column A was also modified to produce the sustained release layer in column C of Table 1. In this formula, colloidal silicon dioxide was removed and citric acid was added. The Ethocel:HPMCAS ratio was decreased from 75:25 to 56:44. This formula was predicted to provide a lower pH in the microenvironment to increase the delay time. One sample layered to produce a 25% weight gain and another sample with a 45% weight gain were subjected to dissolution tests.
[00110] Another embodiment of a sustained release layer was produced in which the drug or API was included in the sustained release layer. This layer is described in column D of Table 1. In this formula, the ratio between Ethocel and HPMCAS was 75:25. A micronized drug was added to the formula as a suspension. A sample with a weight gain of 25% was subjected to dissolution tests.
[00111] Core tablets, as described in Table 2, were coated with a sustained release layer formulated as in column A of Table 1. This formulation showed a slow release of the initial drug (3% in the first 3 hours).
[00112] Another embodiment of a sustained release coating was designed with a ratio of polyethylene oxide (PEO) to ethyl cellulose of 37.5:62.5. Talc was also added to a sample at 10% to improve the coating process. The presence of talc did not affect drug release. Release profiles for these formulations processed with a weight gain of 25% and a weight gain of 40% were also determined. The formulations exhibited a 1 hour delay and the drug was substantially completely released within 9 hours.
[00113] While the disclosed compositions of a capsule containing a single amount of granules or minitablets with a sustained release layer and an outer extended release layer are shown here as an effective delivery system with novel release characteristics and surprisingly low variability in absorbance when administered to humans, it is understood that alternative compositions may be used in light of the present disclosure.
[00114] In certain embodiments, a drug containing a granule or mini-tablet in the core is coated with a sustained release layer that includes one or more water-insoluble polymers, one or more water-soluble polymers, and a silicone oil to achieve a desired extension or desired time delay before being released as in the present disclosure. Latency and release time are controlled by the ratio of the two types of polymers and the layer thickness. In such embodiments, the extended release layer may include, but is not limited to, cellulose acetate phthalate, cellulose acetate trimaleate, hydroxyl-propyl-methylcellulose phthalate, polyvinyl acetate phthalate, acrylic polymers, polyvinyl acetate diethylamino, hydroxypropylmethylcellulose acetate succinate, cellulose acetate trimellitate, shellac, methacrylic acid copolymers, Eudragit L30D, Eudragit L100, Eudragit FS30D, Eudragit S100 or any combination thereof. The extended-release layer may also include a plasticizer, or in certain embodiments the extended-release layer may include Type B methacrylic acid copolymer, mono- and diglycerides, dibutyl sebacate, and polysorbate 80. The extended-release layer may also include a cellulose ether derivative, an acrylic resin, a copolymer of acrylic acid and methacrylic acid esters with quaternary ammonium groups, a copolymer of acrylic acid and methacrylic acid esters, or a combination of any of these. The layer may further include a powder component such as talc as a carrier for the silicone oil.
[00115] In certain embodiments of the invention, a central nervous system stimulant may be contained in a sustained and/or controlled release capsule. In such embodiments a water-insoluble capsule contains one or more compartments, in which the drug or active agent is held. In addition, one or more absorbents, superabsorbents, or osmotic agents are included in drug-containing compartments. The capsules also include one or more openings plugged with a water-soluble polymer, at least one in fluid communication with each compartment, and an extended release layer surrounding the entire capsule.
[00116] In such embodiments, the extent of the initial extension can be controlled by the composition and thickness of the external extended release layer. This layer may be a pH-dependent layer or a pH-independent layer, as disclosed herein. When the capsule is administered to a human, the extended-release layer begins to lose integrity as the capsule passes through the gastrointestinal tract. When the water-soluble buffers are exposed and dissolved, the aqueous fluid enters the compartment(s) containing the drug and is absorbed by the osmotic or absorbent agent, thus driving the active agent from the capsule to the opening. The release profile can be controlled by the concentration and absorption characteristics of the absorbent or osmotic agent to obtain the desired profile. Sustained Release Coatings on Dextroamphetamine Sulfate Pellets
[00117] The formulations of this presentation are produced in which hydrophobic excipients are introduced to obtain an additional prolongation of drug release. The plasticizing agent level is maintained at 7.26% of the EthocelTM level. The formulations are described in Table 3. Table 3 - Controlled Release Formulations


[00118] These formulations were coated at a weight gain level of 30% and the samples were subjected to testing at a dose of 10 mg freebase capsule. The dissolution test was performed in pH 7.0 buffer, with a paddle speed of 75 rpm.
[00119] Lot 2009-066-51 has a water insoluble to water soluble ratio of 80:20. This results in a significantly faster release profile. The API releases 25% in the first hour. In additional formulations the talc was removed and replaced with magnesium stearate.
[00120] Lot 2009-066-53, which contained magnesium stearate, the initial release was significantly slower. Other changes included increasing the level of Ethocel TM in Lot -59 and -64, while decreasing the level of Klucel®. The ratio of Ethocel™ to Klucel® in Batch -59 and -64 respectively is 86:14 and 97:3. This change was expected to delay the release of lot 53, but the dissolution release time actually increased. Lot -67 included a reduction in magnesium stearate and a decrease in the ratio of EthocelTM to Klucel® (return to 80:20). This resulted in a faster release than the model profile.
[00121] Replacement of the hydrophilic plasticizer TEC with dibutyl sebacate (DBS), a hydrophobic plasticizer resulted in significantly greater prolongation prior to initial release. Lot 2009-066-69 was the first batch using DBS as the plasticizing agent. With the addition of DBS and the removal of Klucel®, the initial drug release was less than 2% in 8 hours.
[00122] Klucel® was added back to the formulation of Lot 2009-066-72. The ratio of Ethocel™ to Klucel® was 95:5. The dissolution profile was similar to Lot 2009 - 066-69. In Batch 2009-066-75, the ratio of Ethocel™ to Klucel® decreased from 95:5 to 90:10. This change did not result in a different release profile compared to the two previous formulations.
[00123] For Lot 2009-066-78, the ratio of Ethocel™ to Klucel® was decreased to 80:20 for a higher level of water soluble polymer. Formulation 2009-066-78 showed a drug release of 20% in 4 hours, followed by an increasing release until more than 80% release. DOE Sustained Release Coatings
[00124] An experimental design (DOE) was created with three ratios of Ethocel™ to Klucel®: 70:30, 75:25 and 80:20. Coatings were applied in GPCG2 with a 1.0mm spray nozzle. For a DOE coating 650.0 g of pellets were used. Pellets consisted of 80% w/w placebo pellets and 20% Dextroamphetamine sulfate pellets. The pellets were diluted to preserve the D-amphetamine sulfate pellets. The DOE formulations are shown in Table 4. Each coating formulation contained 12% solids w/w. Solvents consisted of ethanol to deionized water at a ratio of 95:5. Table 4 - DOE formulations


[00125] Each of the DOE formulations was coated to 30% weight gain, then samples were loaded into 13.6 mg dose capsules (equivalent to 10.0 mg dose on a free basis), and subjected to dissolution tests in pH 7.2 phosphate buffer with a paddle speed of 75 rpm (this was the paddle speed for all dissolution tests).
[00126] A standard mixing process has been developed for sustained release coating preparations as follows. Charge the ethanol into an appropriately sized beaker. Place the beaker under a laboratory mixer with a Cowles blade attached. Create a vortex by increasing mixing speed and loading the EthocelTM, Klucel® DBS into the ethanol. The mixer speed is turned down so that there is no vortexing and the excipients are mixed until dissolved. Once the excipients have dissolved, a vortex can be created for the addition of the magnesium stearate. The magnesium stearate is blended for a minimum of 30 minutes or until no more clumps are present. The addition of deionized water to the blended dispersion is the last step in the process. The first eight DOE dissolution profiles are shown in FIG. 4.
[00127] As shown in FIG. 5, DOE 9 had an EthocelTM to Klucel® ratio of 75:25 and produced a faster dissolving release. In DOE 10 the ratio of EthocelTM to Klucel® was 80:20 and the magnesium stearate level was decreased from 40% w/w to 25% w/w. By making these changes, the dissolution profile shifts to the right far beyond the model profile. The formulation of DOE 11 is similar to the formulation of Lot 2009-066-78 (see Table 3 and Table 4 for the formulations). DOE 11, 3 and 4 have release profiles that are close to the model profile. All three have an EthocelTM to Klucel® ratio of 80:20, but differ in percent w/w from the hydrophobic excipients. The DOE 3 coating was the closest profile to the model profile. DOE 3 and DOE 4 stability
[00128] For a stability study, 13.6 mg dose capsules (equivalent to 10.0 mg dose in free base) were loaded into HDPE vials and loaded into the following stability chambers for testing: 40°C /75% RH, 25°C/60% RH and 30°C/65% RH. Pellets were also placed in HDPE vials without capsules at 40°C/75% RH for an open container test. After 2 and 4 weeks for the open container test at 40°C/75% RH, granule dissolution tests were performed in phosphate buffer pH 7.2. The dissolution results are shown in FIG. 6 and fig. 7.
[00129] All dissolution profiles from the different hourly stability programs had similar drug release profiles, which demonstrates that sustained release coatings are stable. The next step in the development consisted of adding a pH-dependent coating on top of the sustained-release coating. pH Dependent Coatings
[00130] For pH dependent coating tests, DOE 3 pellets were used. Samples of 13.6 mg dose (10.0 mg dose on a free base) were filled into capsules. The dissolution test was carried out for 2 hours (T = 0-2 hours) in 0.1N HCl, then in phosphate buffer at pH 6.0 for 4 hours (T = 2-6 hours), and finally , in phosphate buffer at pH 7.0 for the remaining time. The formulations are shown in Table 5. Table 5 - pH Dependent Formulations
1Same formulation as Lot 2009-104-76, but coated at a 4°C higher product temperature.
[00131] S-100 coatings are made with alcohol/Dl water depending on the solvent at 94.4% w/w to 5.6% w/w and the FS 30 D coating is aqueous only. Dissolution profiles are shown in FIG. 8.
[00132] Lot 2009-104-78 featured a 6 hour extension followed by a quick release. Formulation S-100 with GMS (Imwitor 900 K) at 10% w/w was then coated onto DOE 3 pellets. Lot 2009-138-25B shows an initial prolongation of drug release, followed by a release curve which is similar to the template profile. DOE 3 SR Coated Pellets / pH Dependent
[00133] The test with a pH dependent coating on the DOE 3 SR coating was repeated with a batch of 100% active core pellets (no placebo pellets) The coating parameters are shown in Table 6. Table 6: Batch 2009-138-32 - Coating Parameters

[00134] The dissolution profiles of the active and placebo diluted pellets of DOE 3 coatings are shown in Figure 9.
[00135] The pH dependent coating (Lot 2009-138-45) containing GMS was then coated on the sustained release DOE 3 coating. The pellets were coated to a weight gain of 30% with a sample taken at a weight gain of 25%. Pellets were dosed into 13.6 mg capsules (10.0 mg free base) and tested in the 3-stage dissolution study. Coating parameters are in Table 7 and dissolution profiles are shown in FIG. 10. Table 7 - Lot 2009-138-45 - Coating Parameters


[00136] At the time of 10 hours, DOE 3 had released 20% of the drug, which was very close to the target profile. A portion of the DOE 3 pellets (Lot 2009-13845) was encapsulated in gelatin capsules at a dose of 13.6 mg (equivalent to 10 mg dose of free base) and allowed to stand. The bottles were filled with 16 capsules and placed under the following conditions: 4 bottles at 40°C/75% relative humidity, 4 bottles at 30°C/65% relative humidity, one bottle at 25°C/60% relative humidity relative. Two vials containing only pellets equivalent to 16 capsules, placed at 40°C/75% relative humidity for an accelerated open plate test. After stabilizing for two weeks, samples were taken from the open container, 30°C/65% relative humidity and 40°C/75% relative humidity. The dissolution profiles for these samples are shown in Fig. 11.
[00137] The two week open container pellets started releasing drug within 4 hours. The initial granules and the other samples from the closed container did not start to release the drug until after the time of 6 hours. The two samples from the closed container released the drug more slowly than the initial release. The pellets were assumed to have absorbed moisture causing the MSG (Imwitor®) to become unstable and release drug more rapidly in the open container test. To attempt to stabilize the MSG, samples from batch 2009-138-45 were placed in an oven and cured for 12 hours, 24 hours and 48 hours at 50°C. The dissolution results are located in FIG. 12.
[00138] At 50°C, curing time did not affect drug release. Another cure test was created with the oven set at 55°C. Samples from batch 2009-138-45 (DOE 3) were cured for 24, 48 and 108 hours (4.5 days). Dissolution profiles are shown in FIG. 13.
[00139] Drug release after pellet curing at 55°C was not directly time dependent. For samples cured at 55°C, pellets were dosed (13.6 mg/10 mg dose of free base) into gelatin and HPMC capsules. HPMC capsules contain a one gram desiccant in each bottle to absorb any excess moisture. The samples were cured at 50°C only dosed into the HPMC capsules with the desiccant one gram in each vial. Sixteen capsules were introduced into each vial. Stability conditions are shown in Table 8. Table 8 - Stability Conditions for Cured Granules

[00140] After 2 and 4 weeks, the samples cured at 55°C were removed and the dissolution test was performed on them. Dissolution results for the stability samples are shown in FIG. 14.
[00141] For 55°C cured granules loaded into HPMC capsules the dissolution profile for the initial 2 weeks, and the 4 week samples, gave similar results. This demonstrates the stability of the product under these conditions. The gelatin-loaded capsules produced a slightly slower dissolution profile from the initial release in the samples and 2 and 4 weeks.
[00142] Lot 2009-138-45 (DOE 3, SR and pH coated) containing HPMC capsules with desiccant was allowed to stabilize at 40°C/75% RH (closed container) for 8 months. Samples were taken at 2, 3 and 8 months for dissolution tests. The dissolution profiles for the HPMC capsules containing the D-amphetamine sulfate pellets are shown in Fig. 15.
[00143] After 8 months of accelerated stability, D-amphetamine sulfate has a profile similar to the initial release profile (T=0). The only difference is a slower release which is between 7-10 hours. Example 1
[00144] An example of a core pellet as described herein contains the following components produced in a 5 kg batch. Lot size of 5,000 grams 6% Granu ote of 5,000 grams Medium Solids action

[00145] In the process extra water is added to the granulation medium. Water constitutes 47.12% of the dry mix batch amount. The granulation medium is 2506.0 g and the spray speed is 418 ± 20 g/min. Example 2
[00146] An example of a sustained release coating for application to the core pellet is prepared with the following components Core Batch Weight - 1100.0 g Coating Weight % = 30% Solids - 12.0 %
Example 3
[00147] A pH dependent S100 coating formulated for a 30% weight gain is formulated with the following components. Coating weight % - 30% Solids - 10.0% Batch Size - 715 g Core Pellet Quantity - 550 g

Example 4
[00148] A pH dependent coating S100 formulated for a 50% weight gain contains the following components: Coating Weight % - 50.0% Solids - 10.0% Batch Size - 715 g Core Granule Quantity - 550 g
Example 5
[00149] A formulation was made with a pellet core as in Example 1, a sustained release coating as in Example 2 and a pH dependent coating with a 30% weight gain as in Example 3.
Example 6
[00150] A formulation was produced with a pellet core as in Example 1, a sustained release coating as in Example 2 and a pH dependent coating with a 50% weight gain as in Example 3.

Example 7
[00151] An example of a sustained release coating with an alternate ratio of water soluble (Klucel) to water insoluble (Ethocel) polymer is prepared with the following components to obtain a faster release profile. Core batch size - 1100.0 g Coating weight gain - 30% % solids - 12.0%
Example 8
[00152] A formulation was made with a pellet core as in Example 1, a sustained release coating as in Example 7 and a pH dependent coating, with a 30% weight gain as in Example 3.
Example 9
[00153] A formulation was produced with a pellet core as in Example 1, a sustained release coating as in Example 7 and a pH dependent coating with a 50% weight gain as in Example 4.

Example 10
[00154] Another example of a sustained release coating according to the presentation is prepared with the following components. Core batch size - 1100.0 g Coating weight gain - 30% % solids - 12.0%

Example 11
[00155] A formulation with a pellet core as in Example 1, a sustained release coating as in Example 10 and a pH dependent coating was produced with a 30% weight gain as in Example 3.
Example 12
[00156] An example of a starch- or osmotic-free core pellet as described herein contains the following components as produced in a 2 kg batch. These core pellets are used in Examples 17 to 21.

Example 13
[00157] An example of a slow sustained release coating as described herein for use in the slow release formulation (1 and 2) 25%SR + 20% or 30% pH coating. Slow release of SR Coating (1 and 2) Coating weight gain: 25.0% solids: 12.0%
Example 14
[00158] An example of a slow enteric coating, as described herein, for use in the Slow Release Formulation (1 and 2) 25% SR + 20% or 30% pH coating. S100 pH Dependent Coating Slow Release (1) Coating Weight Gain: 20% % Solids: 10% Batch Size (g) 1500 Core Pellet Quantity (g) 1250
Slow Release Coating pH Dependent S100 (2) Coating Weight Gain: 30% % Solids: 10% Batch Size (g) 1625 Amount of Core Granules (g) 1250

Example 15
[00159] An example of a medium sustained release coating as described herein for use in the Medium Release Formulation (1 and 2) 20% SR + 20% or 30% pH coating. Average Release of SR Coating (1 and 2) Coating weight gain: 20% solids: 12%
Average Coating Release pH Dependent S100 (1) Coating Weight Gain: 20.0% Solids: 10.0 Batch Size (g) 1440 Amount of Core Pellets (g) 1000
Average Coating Release pH Dependent S100 (2) Coating Weight Gain: 30% % Solids: 10% Batch Size (g) 1560 Amount of Core Pellets (g) 1200

Example 16
[00160] An example of quick release coatings for the Quick Release Formulation 20% SR + 20% pH coating. SR Coating Quick Release Coating Weight Gain: 20.0% solids: 12
Quick Release Coating pH Dependent S100 Coating Weight Gain: 20% % Solids: 10% Batch Size (g): 1440 Amount of pellets in core (g): 1200
Example 17
[00161] An example of a dextroamphetamine sulfate composition, 30 mg capsules (Slow Release Formulation 1), with a core as described in Example 12, 25% sustained release coating weight gain, + 20% sustained-release (enteric) coating weight gain.

Example 18
[00162] An example of a dextroamphetamine sulfate composition, 30 mg capsules (Slow Release Formulation 2), with a core as described in Example 12, 25% weight gain of sustained release coating, + 30% weight gain of extended release (enteric) coating.
Example 19
[00163] An example of a dextroamphetamine sulfate composition, 30 mg capsules (Medium Release Formulation 1) with a core as described in Example 12, with 20% weight gain of the sustained release coating, + 20% of weight gain of the extended release (enteric) coating.

Example 20
[00164] An example of a dextroamphetamine sulfate composition, 30 mg capsules (Medium Release Formulation 2) with a core as described in Example 12, with 20% sustained release coating weight gain, + 30% of sustained release (enteric) coating weight gain.

Example 21
[00165] An example of a dextroamphetamine sulfate composition, 30 mg capsules (Rapid Release Formulation) with a core as in Example 12, 20% weight gain of sustained release coating, + 20% weight gain of the extended-release (enteric) coating.

Example 22
[00166] The five formulations described in Examples 17 to 21 were subjected to the dissolution test as described. Dissolution data are shown in the table below.

[00167] A graph of dissolution data is shown in FIG. 16. As can be seen from the graph, the formulations provided a sustained release of 6 to 10 hours, followed by an increment of sustained release over the next 10 hours. Example 23
[00168] A parallel, five-arm, single-dose, open-label, fasted trial of 30 mg Dextroamphetamine capsules was performed in healthy, male non-smoking subjects, administering the five formulations described in Examples 13 to 17 for 56 healthy male volunteers aged between 18 and 45 years during each trial.
[00169] Five formulations were administered orally during the test: Treatment A: 1 Capsule of Dextroamphetamine Sulfate 30 mg, CII (coating 20% SR, 30% ER, Medium Release); Treatment B: 1 Capsule of Dextroamphetamine Sulfate 30 mg, CII (25% SR overcoat, 20% ER, Slow Release); Treatment C: 1 Capsule of Dextroamphetamine Sulfate 30 mg, CII (20% SR, 20% ER overcoat, Rapid Release); Treatment D: 1 Capsule of Dextroamphetamine Sulfate 30 mg, CII (25% SR overcoat, 30% ER, Slow Release); Treatment E: 1 Capsule of Dextroamphetamine Sulfate 30 mg, CII (20% SR overcoat, 20% ER, Medium Release);
[00170] Drugs were administered daily at 8:00 am and serum amphetamine concentrations were determined hourly for 20 hours. Using the validated method (D24 Version 00), dextroamphetamine and the internal standard, amphetamine-d5, were extracted from human plasma (200.0 μL), with potassium ethylenediaminetetraacetic acid (K2EDTA) as an anticoagulant, by extraction. liquid-liquid, evaporation under nitrogen atmosphere, and reconstitution in 200.0 μL of the mobile phase (0.05% trifluoroacetic acid: Acetonitrile, 80:20, v/v). An aliquot of this extract was injected into a High Performance Liquid Chromatography (HPLC) system, detected through an API 3000 with an HSID tandem mass spectrometer and quantified using the peak area ratio method.
[00171] The method of sensitivity and selectivity were achieved by detecting the distinct precursor for the ionic mass transitions of the product to dextroamphetamine (136.2 ->119.1) and the internal standard, amphetamine-d5 (141.2 > 124.1), at defined retention times under reverse chromatographic conditions.
[00172] The evaluation of the test, using defined acceptance criteria, was carried out by the construction of a calibration curve of 8 (eight) points (excluding zero concentration), covering the range from 0.200 ng/mL to 51.200 ng/mL for Dextroamphetamine in human plasma The slope and intercept of the calibration curves were determined using weighted linear regression analysis (1/conc2). Two calibration curves and duplicate QC samples (at three concentration levels) were analyzed along with each batch of test samples. Peak area ratios were used to determine the concentration of standards, quality control samples, and unknown test samples from the calibration curves.
[00173] Serum concentrations are shown in FIG. 17, where the start time of day is set to 21 hours. An overlay of pharmacokinetic data from three commercial formulations, Dexedrine, TDAerall XR and Vyvanse are overlaid with data from fig. 17, in FIG. 18.
[00174] As shown in the table below, early exposure from 0 to 6 hours and 0-10 hours was highest for treatment A and is correlated with the early dissolution observed for this formulation. Exposure from 0 to Tmax was marginally greater for treatment A than the other treatments, but was more variable than treatments B and C. Treatment C was greater than treatment B, but more variable. For Treatment D the 0 exposure to Tmax was relatively high (considering total AUC0-inf), however the Tmax values for Treatment D occurred later than for the other treatments.

The mean Tmax values for treatments A, B, C, D and E were 17.9, 16.4, 17.7, 22.6 and 17.8 hours, respectively.
[00175] The early exposure (0-6 and 0-10) given by these formulations was very low relative to the AUC0-inf and is shown in the Table below, along with the AUC0-Tmax, in terms of percentage of mean values of these partial exposure metrics against the mean AUC0-jnf values for each of the five treatments

[00176] Exposure was less than 2% for all treatments (0-6 hours) and less than 5% for AUC (0-10 hours), except for Treatment A (6.4%).
[00177] Seventeen subjects experienced a total of 25 adverse events ("AEs") during the test. The most frequent AEs are expressed as fractions, in relation to the total number of AEs experienced after each treatment.
[00178] No AEs were reported more than once after administration of Treatment A [Dextroamphetamine Sulfate Capsule 30 mg, CII (Medium Release, pH dependent coating 30%, SR 20%)], Treatment C [Dextroamphetamine Sulfate Capsule Dextroamphetamine Sulfate 30 mg, CII (Rapid Release, pH dependent coating 20%, SR 20%)] and Treatment D [Dextroamphetamine Sulfate 30 mg Capsule, CII (Slow Release, pH dependent coating 30%, SR 25%)].
[00179] After administration of Treatment B (30 mg Dextroamphetamine Sulfate Capsule, CII (20% pH dependent coating and 25% SR, Slow Release) the most frequent AEs were headache (2/7) and drowsiness (2/7).
[00180] After administration of Treatment E [(30 mg dextroamphetamine sulfate capsule, CII (20% pH dependent coating, 20% SR, Medium release), the most frequent AE was reported as dry mouth ( 2/8).
[00181] No AE was reported after final examination of tests.
[00182] Five AEs were "probably" related to the test drug, and 12 AEs were "possibly" related to the test drug. All subjects who experienced adverse events during this trial fully recovered.
[00183] There were no serious adverse events (SAEs) reported. Example 24 Methylphenidate Composition, 54 mg Capsules (Slow Release Formulation, 25% SR weight gain + 30% pH dependent weight gain

Example 25 Methylphenidate Composition, 54 mg Capsules (Slow Release Formulation, 20% SR weight gain + 20% pH dependent weight gain

[00184] All compositions and methods described and claimed herein can be produced and performed without undue experimentation in light of the present disclosure. While the compositions and methods of this invention have been described in terms of preferred embodiments, it will be apparent to those skilled in the art that variations may apply to the compositions and/or methods and in the steps, or in the sequence of steps, of the methods described herein without being depart from the concept, scope and scope of the invention. More specifically, it is apparent that some agents that are chemically or physiologically related may be substituted for the agents described herein while obtaining the same or similar results. All such substitutes and similar modifications, which are apparent to those skilled in the art, are intended to fall within the scope, scope and concept of the invention as set forth in the appended claims.

权利要求:
Claims (18)
[0001]
1. Solid oral pharmaceutical composition CHARACTERIZED in that it comprises a plurality of particles, each of which comprises: a core comprising a therapeutic amount of a central nervous system stimulating active ingredient and at least one pharmaceutically acceptable excipient; a sustained release layer surrounding the core; and comprising a water-insoluble and water-permeable polymer and a water-soluble polymer; and an extended release layer surrounding the sustained release layer, wherein the composition provides a period of 4 to 12 hours during which no more than about 10% of the central nervous system stimulating active ingredient is released as measured by the Apparatus. USP I in which the composition is placed in 700 ml of 0.1N aqueous HCl solution, pH 1.1, for up to 2 hours, followed by 2 to 6 hours in sodium phosphate buffer at pH 6.0; followed by 6 to 20 hours in sodium phosphate buffer, pH 7.2 at 37°C ± 0.5°C.
[0002]
2. Oral solid pharmaceutical composition, according to claim 1, CHARACTERIZED by the fact that the in vitro dissolution rate of the dosage form is between 0 and 10% of drug released after 8 hours, between 2 and 30% released after 10 hours, between 15 and 60% released after 12 hours and between 45% and 95% released after 15 hours, and in which the amount of drug released each hour increases from the period between 20% release and 65% release when measured by the USP Method Paddle at 75 rpm in 750 ml of 0.1N aqueous HCl solution for two hours followed by phosphate buffered solution at pH 6.8 and 37°C ± 0.5°C.
[0003]
3. Oral solid pharmaceutical composition, according to claim 1, CHARACTERIZED by the fact that the in vitro dissolution rate of the dosage form is between 0 and 10% of drug released after 6 hours, between 15 and 28% released after 10 hours, between 40 and 60% released after 12 hours and between 80% and 95% released after 15 hours, and where the amount of active ingredient released each hour increases from the period between 20% release and 65% release, when measured by the USP Apparatus I in which the composition is placed in 700 ml of 0.1N aqueous HCl solution, pH 1.1, for up to 2 hours, followed by 2 to 6 hours in sodium phosphate buffer at pH 6.0 ; followed by 6 to 20 hours in sodium phosphate buffer, pH 7.2 at 37 °C ± 0.5 °C.
[0004]
4. Oral solid pharmaceutical composition according to any one of claims 1 to 3, CHARACTERIZED in that not more than 10% of the active ingredient is released within 6 hours and not more than 50% of the active ingredient is released within 12 hours when placed in 0.1N aqueous HCl solution for two hours followed by phosphate buffered solution at pH 6.8 and 37 °C ± 0.5 °C, and wherein, when the composition is administered to in a human, a plot of plasma concentration versus time after administration shows a maximum between 12 and 20 hours after administration.
[0005]
5. Oral solid pharmaceutical composition, according to any one of claims 1 to 4, CHARACTERIZED in that the core comprises amphetamine, dextroamphetamine, methylphenidate, or an isomer, racemic mixture, prodrug or pharmaceutical salt of any one of these.
[0006]
6. Oral solid pharmaceutical composition, according to any one of claims 1 to 5, CHARACTERIZED in that the core comprises one or more excipients selected from polyvinyl pyrrolidone, hydroxypropylmethyl cellulose, lactose, sucrose, microcrystalline cellulose and combinations of any of these .
[0007]
7. Oral solid pharmaceutical composition, according to any one of claims 1 to 6, CHARACTERIZED in that the extended release layer comprises cellulose acetate phthalate, cellulose acetate trimaleate, hydroxypropyl methylcellulose phthalate, methylcellulose acetate phthalate povinyl, acrylic polymers, polyvinyl acetate acetaldiethylamino, hydroxypropyl methylcellulose acetate succinate, cellulose acetate trimellitate, shellac, methacrylic acid copolymers, Eudragit L30D, Eudragit L100, Eudragit FS30D, Eudragit S100 or combinations of any of them of these.
[0008]
8. Oral solid pharmaceutical composition, according to any one of claims 1 to 7, CHARACTERIZED in that the extended release layer comprises a plasticizer selected from dibutyl sebacate (DBS), tributyl citrate, acetyl tributyl citrate, citrate of acetyl triethyl, mineral oil, castor oil or a fixed oil.
[0009]
9. Oral solid pharmaceutical composition, according to any one of claims 1 to 8, CHARACTERIZED in that the extended release layer comprises Type B methacrylic acid copolymer, mono and diglycerides, dibutyl sebacate and polysorbate 80.
[0010]
10. Oral solid pharmaceutical composition, according to any one of claims 1 to 9, CHARACTERIZED in that the sustained release layer comprises a cellulose ether derivative, an acrylic resin, a copolymer of acrylic acid and esters of methacrylic acid with quaternary ammonium groups, a copolymer of acrylic acid and methacrylic acid esters, or a combination of any of these.
[0011]
11. Oral solid pharmaceutical composition, according to any one of claims 1 to 10, CHARACTERIZED in that the sustained release layer comprises ethyl cellulose, hydroxypropyl cellulose and magnesium stearate.
[0012]
12. Oral solid pharmaceutical composition, according to any one of claims 1 to 11, CHARACTERIZED in that it is contained in a water-soluble capsule providing a single dose of the oral solid pharmaceutical composition.
[0013]
13. Oral solid pharmaceutical composition, according to any one of claims 1 to 12, CHARACTERIZED in that it comprises a therapeutic amount of a central nervous system stimulant active ingredient, wherein the composition, when administered orally to a human , provides a sustained release of the central nervous system stimulant active ingredient from 4 to 12 hours, and a maximum serum concentration (Cmax) within 10 to 16 hours after administration.
[0014]
14. Oral solid pharmaceutical composition, according to claim 1, CHARACTERIZED by the fact that the central nervous system stimulant active ingredient is amphetamine, dextroamphetamine or methylphenidate, or an active isomer, racemic mixture, salt or prodrug thereof.
[0015]
15. Oral solid pharmaceutical composition, according to claim 1, CHARACTERIZED by the fact that the therapeutic amount is from 0.1 mg to 1000 mg.
[0016]
16. Oral solid pharmaceutical composition, according to claim 1, CHARACTERIZED by the fact that the therapeutic amount is from 5 mg to 54 mg.
[0017]
17. Use of a composition, as defined in any one of claims 1 to 16, CHARACTERIZED in that it is for the manufacture of a medicament to treat a condition in an individual with a disorder or condition sensitive to the administration of a system stimulant central nervous.
[0018]
18. Use according to claim 17, CHARACTERIZED by the fact that the disorder or condition is attention deficit disorder, attention deficit hyperactivity disorder, excessive daytime sleepiness, major depressive disorder, bipolar depression, negative symptoms in schizophrenia , chronic fatigue, fatigue associated with chemotherapy, or binge eating disorder.

类似技术:

---

公开号 | 公开日 | 专利标题

---

AU2018202002B2|2019-04-04|Methods and compositions for treatment of attention deficit disorder

---

US9023389B1|2015-05-05|Compositions for treatment of attention deficit hyperactivity disorder

---

US10881618B2|2021-01-05|Compositions for treatment of attention deficit hyperactivity disorder

---

US9603809B2|2017-03-28|Methods of treatment of attention deficit hyperactivity disorder

---

US9034902B2|2015-05-19|Methods for treatment of attention deficit hyperactivity disorder

---

US9283214B2|2016-03-15|Compositions for treatment of attention deficit hyperactivity disorder

---

US10292937B2|2019-05-21|Methods of treatment of attention deficit hyperactivity disorder

---

US10905652B2|2021-02-02|Compositions for treatment of attention deficit hyperactivity disorder

---

US11241391B2|2022-02-08|Compositions for treatment of attention deficit hyperactivity disorder

同族专利:

---

公开号 | 公开日

---

CN110151731A|2019-08-23|

---

JP2017128614A|2017-07-27|

---

KR101834033B1|2018-04-13|

---

US9028868B2|2015-05-12|

---

SG10201901167SA|2019-03-28|

---

CN103608004A|2014-02-26|

---

JP6043785B2|2016-12-14|

---

AU2016228307A1|2016-10-06|

---

CA2830788A1|2012-09-27|

---

KR20140030158A|2014-03-11|

---

EP2688557A1|2014-01-29|

---

AU2018202002B2|2019-04-04|

---

PT2688557T|2017-11-23|

---

BR112013024401A2|2017-11-07|

---

MX2013010920A|2014-08-29|

---

JP2016117767A|2016-06-30|

---

CA2830788C|2016-05-17|

---

EP2688557A4|2014-09-24|

---

DK2688557T3|2017-11-27|

---

JP2014508812A|2014-04-10|

---

JP6325148B2|2018-05-16|

---

ES2644942T3|2017-12-01|

---

US20120276017A1|2012-11-01|

---

KR20160135373A|2016-11-25|

---

WO2012129551A1|2012-09-27|

---

EP2688557B1|2017-08-23|

---

EP3272342A1|2018-01-24|

---

MX357551B|2018-07-13|

---

SG193587A1|2013-10-30|

---

ZA201307649B|2014-06-25|

---

AU2018202002A1|2018-04-12|

---

DK3272342T3|2021-06-07|

---

EP3272342B1|2021-05-26|

---

JP2020079322A|2020-05-28|

---

AU2012230733A1|2013-10-17|

---

ES2883589T3|2021-12-09|

---

AU2012230733B2|2016-10-20|

---

JP2018197276A|2018-12-13|

---

PT3272342T|2021-07-12|

引用文献:

---

公开号 | 申请日 | 公开日 | 申请人 | 专利标题

---

---

GB8322007D0|1983-08-16|1983-09-21|Wellcome Found|Pharmaceutical delivery system|

---

US4904476A|1986-03-04|1990-02-27|American Home Products Corporation|Formulations providing three distinct releases|

---

US5474783A|1988-03-04|1995-12-12|Noven Pharmaceuticals, Inc.|Solubility parameter based drug delivery system and method for altering drug saturation concentration|

---

EP0458887A1|1989-02-16|1991-12-04|Btg International Limited|Dispensing device|

---

JP2558396B2|1990-06-28|1996-11-27|田辺製薬株式会社|Controlled release formulation|

---

US5266331A|1991-11-27|1993-11-30|Euroceltique, S.A.|Controlled release oxycodone compositions|

---

US5656295A|1991-11-27|1997-08-12|Euro-Celtique, S.A.|Controlled release oxycodone compositions|

---

US5260068A|1992-05-04|1993-11-09|Anda Sr Pharmaceuticals Inc.|Multiparticulate pulsatile drug delivery system|

---

NZ260408A|1993-05-10|1996-05-28|Euro Celtique Sa|Controlled release preparation comprising tramadol|

---

JP2916978B2|1993-08-25|1999-07-05|エスエス製薬株式会社|Controlled release initiation type formulation|

---

US5658590A|1995-01-11|1997-08-19|Eli Lilly And Company|Treatment of attention-deficit/hyperactivity disorder|

---

IT1276689B1|1995-06-09|1997-11-03|Applied Pharma Res|SOLID PHARMACEUTICAL FORM FOR ORAL USE|

---

GB9514451D0|1995-07-14|1995-09-13|Chiroscience Ltd|Sustained-release formulation|

---

US5837284A|1995-12-04|1998-11-17|Mehta; Atul M.|Delivery of multiple doses of medications|

---

US5922736A|1995-12-04|1999-07-13|Celegene Corporation|Chronic, bolus administration of D-threo methylphenidate|

---

US6355656B1|1995-12-04|2002-03-12|Celgene Corporation|Phenidate drug formulations having diminished abuse potential|

---

US5908850A|1995-12-04|1999-06-01|Celgene Corporation|Method of treating attention deficit disorders with d-threo methylphenidate|

---

MX9805870A|1996-01-22|1999-01-31|

---

DE69716713T2|1996-02-02|2003-07-03|Medeva Europ Ltd|METHOD FOR PRODUCING D-THREO- METHYLPHENIDATE AND RECYCLING UNWANTED ENANTIOMERS BY EPIMERIZATION|

---

ES2173422T3|1996-03-08|2002-10-16|Medeva Europ Ltd|DISRECIATION OF TREO-METHYLPHENIDATE.|

---

GB9606417D0|1996-03-27|1996-06-05|Chiroscience Ltd|Asymmetric cyclisation|

---

PT932388E|1996-09-30|2006-07-31|Alza Corp|DOSAGE AND METHOD FOR ADMINISTRATION OF DRUGS|

---

US6919373B1|1996-11-12|2005-07-19|Alza Corporation|Methods and devices for providing prolonged drug therapy|

---

EP1782798A3|1996-11-25|2008-05-21|Alza Corporation|Ascending-dose dosage form|

---

DE69735848T2|1996-11-25|2006-12-28|Alza Corp., Palo Alto|DOSE FORM WITH INCREASING DOSE RELIEF|

---

HU0001604A3|1996-12-13|2003-03-28|Medeva Europ Ltd|The preparation of an enantiomerically-enriched threo-methylphenidate|

---

GB9700912D0|1997-01-17|1997-03-05|Chiroscience Ltd|Resolution|

---

US6210705B1|1997-12-15|2001-04-03|Noven Pharmaceuticals, Nc.|Compositions and methods for treatment of attention deficit disorder and attention deficit/hyperactivity disorder with methylphenidate|

---

US6524620B2|1998-07-20|2003-02-25|Andrx Pharmaceuticals, Inc.|Diltiazem controlled release formulation and method of manufacture|

---

EP2266542A3|1998-10-01|2013-07-31|Elan Pharma International Limited|Controlled release nanoparticulate compositions|

---

US6322819B1|1998-10-21|2001-11-27|Shire Laboratories, Inc.|Oral pulsed dose drug delivery system|

---

ES2313797T7|1998-11-02|2019-11-19|Alkermes Pharma Ireland Ltd|Multiparticulate modified release composition of methyl fenidate|

---

US6419960B1|1998-12-17|2002-07-16|Euro-Celtique S.A.|Controlled release formulations having rapid onset and rapid decline of effective plasma drug concentrations|

---

US6733789B1|1999-01-21|2004-05-11|Biovail Laboratories, Inc.|Multiparticulate bisoprolol formulation|

---

US8545880B2|1999-02-26|2013-10-01|Andrx Pharmaceuticals, Llc|Controlled release oral dosage form|

---

US6384020B1|1999-07-14|2002-05-07|Shire Laboratories, Inc.|Rapid immediate release oral dosage form|

---

US6500459B1|1999-07-21|2002-12-31|Harinderpal Chhabra|Controlled onset and sustained release dosage forms and the preparation thereof|

---

GB9918735D0|1999-08-09|1999-10-13|Straken Limited|Transdermal patches|

---

US6898455B2|1999-10-29|2005-05-24|The Mclean Hospital Corporation|Method for providing optimal drug dosage|

---

US7108866B1|1999-12-10|2006-09-19|Biovall Laboratories International Srl|Chronotherapeutic diltiazem formulations and the administration thereof|

---

US6569456B2|2000-01-13|2003-05-27|Osmotica Corp.|Osmotic device containing diltiazem and an ACE inhibitor or diuretic|

---

US6627223B2|2000-02-11|2003-09-30|Eurand Pharmaceuticals Ltd.|Timed pulsatile drug delivery systems|

---

US6520921B1|2000-06-20|2003-02-18|Eastman Kodak Company|Method for determining attention deficit hyperactivity disorder medication dosage and for monitoring the effects of medication|

---

US6344215B1|2000-10-27|2002-02-05|Eurand America, Inc.|Methylphenidate modified release formulations|

---

US20030232890A1|2000-11-01|2003-12-18|Sention, Inc.|Methods for treating an impairment in memory consolidation|

---

US6287599B1|2000-12-20|2001-09-11|Shire Laboratories, Inc.|Sustained release pharmaceutical dosage forms with minimized pH dependent dissolution profiles|

---

US20040137062A1|2001-05-25|2004-07-15|Sham Chopra|Chronotherapy tablet and methods related thereto|

---

US7195778B2|2001-07-10|2007-03-27|Teva Pharmaceutical Industries Ltd.|Drug delivery system for zero order, zero order-biphasic, ascending or descending drug delivery|

---

US7157103B2|2001-08-06|2007-01-02|Euro-Celtique S.A.|Pharmaceutical formulation containing irritant|

---

US6811794B2|2001-12-20|2004-11-02|Shire Laboratories, Inc.|Sustained release pharmaceutical dosage forms with minimized pH dependent dissolution profiles|

---

US7659253B2|2002-02-22|2010-02-09|Shire Llc|Abuse-resistant amphetamine prodrugs|

---

US7105486B2|2002-02-22|2006-09-12|New River Pharmaceuticals Inc.|Abuse-resistant amphetamine compounds|

---

US7700561B2|2002-02-22|2010-04-20|Shire Llc|Abuse-resistant amphetamine prodrugs|

---

US6726624B2|2002-03-06|2004-04-27|The Mclean Hospital Corporation|Method and apparatus for determining attention deficit hyperactivity disorder medication dosage and for monitoring the effects of adhd medication on people who have adhd using complementary tests|

---

US7776314B2|2002-06-17|2010-08-17|Grunenthal Gmbh|Abuse-proofed dosage system|

---

MXPA05002623A|2002-09-09|2005-05-05|Biovail Lab Inc|Chronotherapeutic diltiazem formulations and the administration thereof.|

---

US6913768B2|2002-09-24|2005-07-05|Shire Laboratories, Inc.|Sustained release delivery of amphetamine salts|

---

US7988993B2|2002-12-09|2011-08-02|Andrx Pharmaceuticals, Inc.|Oral controlled release dosage form|

---

EP1589951B1|2003-01-03|2017-08-09|Supernus Pharmaceuticals, Inc.|Use of a mixture of two or more enteric materials to regulate drug release via membrane or matrix for systemic therapeutics|

---

SI1644019T2|2003-05-29|2018-04-30|Shire Llc|Abuse resistant amphetamine compounds|

---

US20050031688A1|2003-08-04|2005-02-10|Ayala William J.|Positive wakeup pharmaceutical sleep system with compatible pre-bedtime administration|

---

CA2596035A1|2005-01-28|2006-08-03|Collegium Pharmaceutical, Inc.|Non-ionic non-aqueous vehicles for topical and oral administration of carrier-complexed active agents|

---

ES2299995T3|2004-01-29|2008-06-01|Pfizer, Inc.|DERIVATIVES OF 1-ISOPROPIL-2-OXO-1,2-DIHYDROPIRIDINE-3-CARBOXAMIDE WITH RECEPTOR AGONIST ACTIVITY 5-HT4.|

---

ES2261006B1|2004-06-10|2007-11-01|Laboratorios Rubio, S.A.|PELLET MULTICAPA CONTROLLED RELEASE OF METHYLPHENIDATE|

---

FR2891459B1|2005-09-30|2007-12-28|Flamel Technologies Sa|MICROPARTICLES WITH MODIFIED RELEASE OF AT LEAST ONE ACTIVE INGREDIENT AND ORAL GALENIC FORM COMPRISING THE SAME|

---

FR2892937B1|2005-11-10|2013-04-05|Flamel Tech Sa|MICROPARTICULAR ORAL PHARMACEUTICAL FORM ANTI-MEASURING|

---

PL2457562T3|2006-05-09|2017-09-29|Mallinckrodt Llc|Zero-order modified release solid dosage forms|

---

ES2529455T3|2006-05-12|2015-02-20|Shire Llc|Drug delivery system by controlled doses|

---

US8846100B2|2006-05-12|2014-09-30|Shire Llc|Controlled dose drug delivery system|

---

FR2901478B1|2006-05-24|2015-06-05|Flamel Tech Sa|MULTIMICROPARTICULATED ORAL PHARMACEUTICAL FORM WITH PROLONGED RELEASE|

---

CN1985810A|2006-07-28|2007-06-27|中国人民解放军第二军医大学|Slow control released methylphenidate hydrochloride capsule and its preparing method|

---

KR100888131B1|2006-10-10|2009-03-11|한올제약주식회사|Combination preparation for Cardiovascular disease therapy by Chronotherapy theory.|

---

CA2664893C|2006-10-30|2015-01-27|Hanall Pharmaceutical Company, Ltd.|Controlled release complex composition comprising angiotensin-ii-receptor blockers and hmg-coa reductase inhibitors|

---

JP5553747B2|2007-04-04|2014-07-16|シグモイド・ファーマ・リミテッド|Cyclosporine pharmaceutical composition|

---

WO2009035473A2|2007-09-13|2009-03-19|Sanfilippo Louis C|Method of treating binge eating disorder, obesity resulting from binge eating behavior and depressive disorders|

---

US8383152B2|2008-01-25|2013-02-26|Gruenenthal Gmbh|Pharmaceutical dosage form|

---

CA2627198A1|2008-03-27|2009-09-27|Pharmascience Inc.|Methylphenidate extended release therapeutic drug delivery system|

---

EP2488029B1|2009-09-30|2016-03-23|Acura Pharmaceuticals, Inc.|Methods and compositions for deterring abuse|US5049382A|1989-04-14|1991-09-17|The United States Of America As Represented By The Secretary Of The Navy|Coating and composition containing lipid microstructure toxin dispensers|

---

US9498447B2|2011-03-23|2016-11-22|Ironshore Pharmaceuticals & Development, Inc.|Compositions for treatment of attention deficit hyperactivity disorder|

---

US11241391B2|2011-03-23|2022-02-08|Ironshore Pharmaceuticals & Development, Inc.|Compositions for treatment of attention deficit hyperactivity disorder|

---

US10905652B2|2011-03-23|2021-02-02|Ironshore Pharmaceuticals & Development, Inc.|Compositions for treatment of attention deficit hyperactivity disorder|

---

US9119809B2|2011-03-23|2015-09-01|Ironshore Pharmaceuticals & Development, Inc.|Compositions for treatment of attention deficit hyperactivity disorder|

---

US10292937B2|2011-03-23|2019-05-21|Ironshore Pharmaceuticals & Development, Inc.|Methods of treatment of attention deficit hyperactivity disorder|

---

GB201319791D0|2013-11-08|2013-12-25|Sigmoid Pharma Ltd|Formulations|

---

CA2936746C|2014-10-31|2017-06-27|Purdue Pharma|Methods and compositions particularly for treatment of attention deficit disorder|

---

WO2017027778A1|2015-08-13|2017-02-16|Temple University-Of The Commonwealth System Of Higher Education|Calcium alginate dosage formulations, and methods of making and using thereof|

---

US9849125B1|2015-11-03|2017-12-26|Banner Lifie Sciences LLC|Anti-overingestion dosage forms|

---

WO2017173068A1|2016-03-30|2017-10-05|University Of Maryland, Baltimore|Microparticulate system for colonic drug delivery|

---

EP3439657A4|2016-05-26|2019-12-18|Ovid Therapeutics Inc|Methods of treating behavioral syndromes using pipradrol|

---

CA3028450A1|2016-07-06|2018-01-11|Durect Corporation|Oral dosage form with drug composition, barrier layer and drug layer|

---

US9931303B1|2017-02-06|2018-04-03|Alcobra Ltd.|Abuse deterrent formulations of amphetamine|

---

EP3616696A4|2017-04-28|2021-01-27|Astellas Pharma Inc.|Orally administrable enzalutamide-containing pharmaceutical composition|

---

US10335375B2|2017-05-30|2019-07-02|Patheon Softgels, Inc.|Anti-overingestion abuse deterrent compositions|

---

CN108653243B|2018-03-30|2019-03-22|江苏南农高科动物药业有限公司|A kind of preparation method being sustained Tilmicosin microcapsule powder|

---

US10722473B2|2018-11-19|2020-07-28|Purdue Pharma L.P.|Methods and compositions particularly for treatment of attention deficit disorder|

---

EP3662900A1|2018-12-07|2020-06-10|Tillotts Pharma AG|Colonic drug delivery formulation|

---

EP3914248A1|2019-01-25|2021-12-01|Ironshore Pharmaceuticals & Development, Inc.|Methylphenidate compositions for treatment of attention deficit hyperactivity disorder|

法律状态:
2018-01-23| B07D| Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]|

---

2018-04-03| B06F| Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]|

---

2019-03-26| B07E| Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]|Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |

---

2019-06-04| B06T| Formal requirements before examination [chapter 6.20 patent gazette]|

---

2021-07-20| B06A| Patent application procedure suspended [chapter 6.1 patent gazette]|

---

2021-10-26| B09A| Decision: intention to grant [chapter 9.1 patent gazette]|

---

2022-01-11| B16A| Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]|Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 23/03/2012, OBSERVADAS AS CONDICOES LEGAIS. |

优先权:

---

申请号 | 申请日 | 专利标题

---

US201161466684P| true| 2011-03-23|2011-03-23|

---

US61/466,684|2011-03-23|

---

US201161561763P| true| 2011-11-18|2011-11-18|

---

US61/561,763|2011-11-18|

---

US201261591129P| true| 2012-01-26|2012-01-26|

---

US61/591,129|2012-01-26|

---

PCT/US2012/030472|WO2012129551A1|2011-03-23|2012-03-23|Methods and compositions for treatment of attention deficit disorder|

---